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Chapter I
Introduction
INTRODUCTION
The commonly used and most convenient method of drug delivery is  oral
route of drug administration . Despite tremendous advancements in drug delivery the
oral route remains the preferred route of administration of therapeutic agents
because of low cost of therapy and ease of administration leading to high levels of
patient compliance. However, this route has several physiological problems,
including an unpredictable gastric emptying rate that varies, a brief gastrointestinal
transit time, poor bioavailability and the existence of an absorption window in the
upper small intestine for several drugs 1.
These difficulties have prompted researchers to design a drug delivery
system which can remain in the stomach for prolonged and predictable period.
Attempts are being made to develop a controlled drug delivery system, which can
provide drug release at a pre determined, predictable and controlled rate. The
denovo design of an oral CDDS should be primarily aimed at achieving more
predictable and increased bioavailability of drugs2.  For the successful performance
of oral CRDDS the drug should have good absorption throughout the GIT,
preferably by passive diffusion.
One of the most feasible approaches for achieving a prolonged and
predictable drug delivery profiles in GIT is to control the Gastric residence time
(GRT) using gastro retentive dosage forms (GRDFS) that offer a new and better
option for drug therapy.
1.1. Gastroretentive drug delivery system
Dosage forms which retained in the stomach for an extended period of time
are called Gastro retentive dosage forms. These systems allow both time control and
spatial drug liberation. GRDDS can improve the controlled delivery of drugs that
have an absorption window by continuously releasing the drug for a prolonged
period of time before it reaches to its absorption site thus ensuring its optimal
bioavailability, prolonged gastric retention improves bioavailability, reduces drug
waste and improves the solubility of drugs that are less soluble in acidic pH
environment.
Gastro retention helps to provide better availability of new products
with new therapeutic possibilities and substantial benefits for patients. GRDFS can
be used as carriers for drugs with so called absorption windows. These substances
for example antiviral, antifungal and antibiotic agents (Cephalosporin’s, Quinolones,
Penicillin’s, Sulphonamides, Amino glycosides, Tetracycline’s etc) are taken up
only from very specific sites of GIT.   GRDFS can also have application in the for
local drug delivery to the stomach and small intestine.
The controlled Gastric retention of solid dosage forms may achieved
by the mechanism of Mucoadhesion, Floatation, Sedimentation, Expansion,
Modified shaped systems or by the simultaneous administration of Pharmacological
agents that delay the gastric emptying.
1.1.1 Potential drug used for Gastroretentive drug delivery systems
 Drugs those are locally active in the stomach.
E.g.  Misroprostol, Antacids etc.
 Drugs that have narrow absorption window in gastrointestinal tract (GIT).
E.g.  L-DOPA,  Para aminobenzoic acid, Furosemide, Riboflavin etc.
 Drugs those are unstable in the intestinal or colonic environment.
E.g.  Captopril, Ranitidine HCl, Metronidazole etc.
 Drugs that disturb normal colonic microbes.
E.g. Antibiotics against Helicobacter pylori. Etc.
 Drugs that exhibit low solubility at high PH values.
E.g. Diazepam, Chlordiazepoxide etc.
1.1.2 Drugs those are unsuitable for Gastro-retentive drug delivery system
 Drugs intended for selective release in the colon.
E.g.   5-aminosalicylic acid and Corticosteroids etc.
 Drugs that have very limited acid solubility.
E.g.   Phenytoin etc.
 Drugs that suffer instability in the gastric environment.
E.g. Erythromycin etc 3.
1.1.3 Drugs that would benefit from Gastro-retentive drug delivery
 CNS drugs (for Parkinson disease, epilepsy, Alzheimer and migraine).
 Anti-viral products (for HIV, herpes and hepatitis) and certain antibiotics.
 Anti-hypertension drugs.
 Anti-diabetic agents for Type 2 diabetes.
 Drugs for local treatment of GI infections and gastric enzyme replacement 4.
1.1.4 Advantages of Gastroretentive drug delivery systems
 Enhanced bioavailability
 Better drug utilization.
 Improved efficiency in the treatment.
 Improved patient compliance.
 Site specific drug delivery.
 Sustained drug delivery / reduced frequency dosing.
 Reduced fluctuations of drug concentration.
 Absorption enhancement.
 Minimized adverse effects at the colon.
1.1.5 Limitations
 The major disadvantage of floating system is requirement of a sufficient high
level of fluids in the stomach for the drug delivery to float.
 Drugs having irritant effect on gastric mucosa is not suitable candidates.
 Floating system is not feasible for those drugs that have solubility or stability
problem in gastric fluids.
 Drugs which are absorbed along the entire GIT and which undergo first pass
metabolism may not be desirable E.g. Nifedipine 5.
1.2   Basic Gastrointestinal tract physiology
Anatomically the stomach is divided into 3 regions: fundus, body, and antrum
(pylorus). The proximal part made of fundus and body acts as a reservoir for
undigested material, whereas the antrum is the main site for mixing motions and act
as a pump for gastric emptying by propelling actions.
Gastric emptying occurs during fasting as well as fed states. The pattern of
motility is however distinct in the 2 states. During the fasting state an interdigestive
series of electrical events take place, which cycle both through stomach and intestine
every 2 to 3 hours.14 this is called the interdigestive myloelectric cycle or migrating
myloelectric cycle (MMC), which is further divided into following 4 phases 7.
1. Phase I (basal phase) lasts from 40 to 60 minutes with rare contractions.
2. Phase II (preburst phase) lasts for 40 to 60 minutes with intermittent action
potential and contractions. As the phase progresses the intensity and frequency also
increases gradually.
3. Phase III (burst phase) lasts for 4 to 6 minutes. It includes intense and regular
contractions for short period. It is due to this wave that all the undigested material is
swept out of the stomach down to the small intestine. It is also known as the
housekeeper wave.
4. Phase IV lasts for 0 to 5 minutes and occurs between phases III and I of 2
consecutive cycles.
After the ingestion of a mixed meal, the pattern of contractions changes from fasted
to that of fed state. This is also known as digestive motility pattern and comprises
continuous contractions as in phase II of fasted state. These contractions result in
reducing the size of food particles (to less than 1 mm), which are propelled toward
the pylorus in a suspension form. During the fed state onset of MMC is delayed
resulting in slowdown of gastric emptying rate6.
Figure 1: Gastrointestinal motility pattern.
Different features of the stomach:
 Gastric PH : Fasted healthy subject 1.1±0.15
Fed healthy subject 3.6±0.4
 Volume :  Resting volume is about 25-50 ml
 Gastric secretion: Acid, Pepsin, Gastrin, Mucus, and Some enzymes about
60ml with approximately 4 mol of hydrogen ions per hour.
Table1: Salient features of upper gastrointestinal tract
Parameter Stomach Small Intestine
pH range 1-4 5-7.5
Length (cms) 20 285
Diameter (cms) 15 2.5
Blood flow (L/min) 0.15 1.0
Microbial <103 103-1010
Transit time (hours) Variable 3±1
Absorbing Surface
area (sq.mm)
0.1-0.2 120-200
Absorptive
mechanisms
Passive diffusion,
convective transport
All absorption
mechanisms
1.3 Concept of Absorption Window
A major constraint in oral CRRDS is that not all the drugs are absorbed uniformly
throughout the GIT. Some drugs are absorbed in a particular portion of GIT only or
absorbed to a different extent in various segments of gastrointestinal tract. Such
drugs are said to have absorption window. Thus, only the drug released in the region
preceding and in close vicinity to the absorption window is available for absorption
after crossing the absorption window, the released drug goes to waste with
negligible or no absorption. This phenomenon drastically decreases the available
drug for absorption, after release of drug from CRDDS. The CRDDS possessing the
ability of being retained in the stomach are called GRDDS and they can help in
optimizing the oral controlled delivery of drugs having absorption window by
continuously releasing drug prior to absorption window, for prolonged period of
time thus ensuring optimal bioavailability 8.
Figure 2: (a) Conventional drug delivery system, (b) GRDDS.
This absorption window is observed due to following factors
1) Physico chemical factors
a) pH- dependant solubility
b) pH-dependant stability
c) Enzymatic degradation
2) Physiological factors
a) Mechanism of absorption
b) Microbial degradation
3) Biochemical factors
a) Intestinal metabolic enzymes, cytochrome P450 (CYP3A)
b) Multi drug efflux pump, P-glycoprotein (PGP) present in the villus
Tip of enterocytes in the GIT 9.
1.4 Factors Affecting the Gastro retentive System:
Various attempts have been made to retain the dosage form in the stomach as
a way of increasing the retention time. These attempts include use of floating dosage
forms (gas-generating systems and swelling or expanding systems), mucoadhesive
systems, high-density systems, modified shape systems, gastric-emptying delaying
devices and co-administration of gastric-emptying delaying drugs. Most of these
approaches are influenced by a number of factors that affect their bioavailability and
efficacy of the gastro retentive system.
Figure 3: Schematic Representation of an intragastric floating system and a
high density system in the stomach
 Density – Gastric retention time (GRT) is a function of dosage form
buoyancy that is dependent on the density.
 Size – Dosage form units with a diameter of more than 7.5 mm are reported
to have an increased GRT compared with those with a diameter of 9.9 mm10.
 Shape of dosage form – Tetrahedron and ring shaped devices with a flexural
modulus of 48 and 22.5 kilo pounds per square inch (KSI) are reported to
have better GRT 90% to 100% retention at 24 hours compared with other
shapes.
 Single or multiple unit formulation – Multiple unit formulations show a
more predictable release profile and insignificant impairing of performance
due to failure of units, allow co-administration of units with different release
profiles or  containing incompatible substances and permit a larger margin of
safety against dosage form failure compared with single unit dosage forms.
 Fed or unfed state – Under fasting conditions, the GI motility is
characterized by periods of strong motor activity or the migrating
myoelectric complex (MMC) that occurs every 1.5 to 2 hours. The MMC
sweeps undigested material from the stomach and, if the timing of
administration of the formulation coincides with that of the MMC, the GRT
of the unit can be expected to be very short. However, in the fed state, MMC
is delayed and GRT is considerably longer11.
 Nature of meal – Feeding of indigestible polymers or fatty acid salts can
change the motility pattern of the stomach to a fed state, thus decreasing the
gastric emptying rate and prolonging drug release.
 Caloric content – GRT can be increased by 4 to10 hours with a meal that is
high in proteins and fats
 Frequency of feed – The GRT can increase by over 400 minutes when
successive meals are given compared with a single meal due to the low
frequency of MMC.
 Gender – Mean ambulatory GRT in males (3.4±0.6 hours) is less compared
with their age and race matched female counterparts (4.6±1.2 hours),
regardless of the weight, height and body surface.
 Age – Elderly people, especially those over 70, have a significantly longer
GRT.
 Posture – GRT can vary between supine and upright ambulatory states of
the patient.
 Concomitant drug administration – Anticholinergics like atropine and
propantheline, opiates like codeine and prokinetic agents like
metoclopramide and cisapride can affect floating time.
 Biological factors – Diabetes and Crohn’s disease, etc. also influences
gastric retention12.
Table2: List of drugs formulated as single and multiple unit forms of floating
drug  delivery systems13
Dosage forms Drugs
Tablets Acetaminophen, Acetylsalicylic acid, Ampicillin, Amoxicillin
trihydrate, Atenolol, Captopril, Cinnerzine, Chlorpheniramine
maleate, Ciprofloxacin, Diltiazem, Fluorouracil, Isosorbide di
nitrate, Isosorbid mononitrate, p -Aminobenzoic acid(PABA),
Prednisolone, Nimodipine,  Sotalol, Theophylline,Verapamil
Capsules Pepstatin Verapamil HCl, Chlordiazepoxide HCl, Diazepam ,
Furosemide, L-Dopa, benserazide, Misoprostol Propranolol HCl ,
Ursodeoxycholic acid , Nicardipine
Granules Prednisolone Cinnarizin , Diclofenac sodium, Diltiazem,
Indomethacin, Fluorouracil, Prednisolone Isosorbide mononitrate
, Isosorbide dinitrate
Microsphere Aspirin, Griseofulvin, p-nitro aniline, Ibuprofen,
Terfenadine, Tranilast
Powders Riboflavin-59-phosphate Sotalol,Theophylline
Films p-Aminobenzoicacid, Cinnarizine, Piretanide, Prednisolone,
Quinidine gluconate
Table: 3   Marketed preparations of Gastro retentive technologies available in
the International market
Brand Name Active Ingredient Remarks
Glumetza Metformin Polymer based
Cifran OD Ciprofloxacin Gas generating floating form
Pro QuinXR Ciprofloxicin Polymer based
Gabapentin GR Gabapentin Polymer based expandable film
filled in capsule.
Baclofen GRS Baclofen Coated multilayer floating
&swelling system
CoregCR
(carvedilol)
Carvedilol Gastro retention with Osmotic
system
Madopar L-DOPA-and
Bensarazide
Floating Controlled Release
capsules
Valrelease Diazepam Floating capsule
Topalkan Aluminu-magnesium
antacid
Floating Liquid alginate
preparation.
Almagate FlatCoat Aluminu-magnesium
antacid
Floating Dosage form
Liquid Gavison Aluminium hydroxide Effervescent floating
Liquid alginate preparation.
Cytotec Misoprostal Biilayer floating capsule
1.5 Different Techniques of Gastric Retention
Various techniques have been made to retain the dosage form in the stomach as a
way of increasing the retention time. These techniques include, floating dosage
forms14, swelling and expanding system, mucoadhesive systems , high density
system modified shape systems Gastric emptying delaying devices and co-
administration of gastric delaying drugs15,16. Among these, the floating dosage forms
have been used most commonly.
I). High-density systems
II). Floating systems
III). Superporous hydrogels
IV). Swellable systems
V). Bioadhesive or mucoadhesive systems
VI). Magnetic systems17
Figure 4: Different Gastroretentive systems in the Gastrointestinal tract.
I) High-density systems
These formulations have a density of 2.4-2.8 g/cm3 greater than the stomach
contents. (1.004 g /cm3). When the patient is upright small high-density pellets sink
to the bottom of the stomach where they become entrapped in the folds of the
antrum and withstand the peristaltic waves of the stomach wall. A density close to
2.5 g/cm3 seems necessary for significant prolongation of gastric residence time18.
Drawback:  these are technically difficult to manufacture, with a large amount of
drug (>50%) and to achieve the required density of 2.4-2.8 g/cm3. Barium sulphate,
zinc oxide, iron powder, titanium dioxide are used as excipients.
II) Floating Drug Delivery System
The concept of FDDS was described in the literature as early as 1962. Floating
drug delivery systems is one of the important approaches to achieve gastric retention
to obtain sufficient drug bioavailability. These delivery systems is desirable for
drugs with an absorption window in the stomach or in the upper small intestine19
.FDDS have a bulk density less than gastric fluids and so remain buoyant in the
stomach without affecting the gastric emptying rate for a prolonged period of time.
While the system is floating on the gastric contents the drug is released slowly at the
desired rate from the system. This results in an increased GRT and a better control
of fluctuations in plasma drug concentration.
Formulation of this device must comply with the following criteria
1) It must have sufficient structure to form a cohesive GIT barrier.
2) It must maintain an overall specific gravity lower than that of gastric contents
(1.004-1.010).
3) It should dissolve slowly enough to serve as a drug reservoir20.
Figure 5:  Mechanism of floating system
Types of Floating Drug Delivery Systems
Based on the mechanism of buoyancy two distinctly different technologies have
been
Utilized in the development of FDDS.
1)  Effervescent FDDS
2)  Non- Effervescent FDDS
1)   Effervescent floating dosage forms
A.   Gas generating Systems
These are the matrix types of systems which are prepared by using swellable
polymers like methylcellulose, HPMC and Chitosan based polymers as well as
various effervescent compounds like sodium carbonate, calcium carbonate, tartaric
acid and citric acid21 .They are formulated in such a way that when in contact with
the acidic gastric contents, CO2 liberated and gets entrapped in  the swollen
hydrocolloids, which provides buoyancy to the dosage forms.
i) Single unit systems (Tablets and capsules)
1 In these systems effervescent substances are incorporated in the hydrophilic
polymer, and co2bubbles are trapped in the swollen matrix22 .
2 Bilayer or multilayer systems have also been designed. in these systems drug
and excipients can be formulated independently and the gas generating unit
can be incorporated into any of the layers.
3 Further refinements involve coating the matrix with a polymer which is
permeable to water, but not to co223.
Figure 6: Monolayer drug delivery system (a) Bi layer gas generating system,
with(c) or without (b) semipermiable membrane.
ii)  Multiple unit type Floating Pills
The system consists of sustained release pills as ‘seeds’ surrounded by
double layers. The inner layer consists of effervescent agents while the outer layer is
of swellable membrane layer. When the system is immersed in dissolution medium
at body temp, it sinks at once and then forms swollen pills like balloons, which float
as they have lower density. This lower density is due to generation and entrapment
of CO2 within the system24.
Figure7: Schematic Representation of floating a pill. (A) Different layers. (B).
Mechanism of floatation via gastric retention.
iii) Floating System with Ion-Exchange resins
A floating system using ion exchange resin that was loaded with bicarbonate
by mixing the beads with 1M sodium bicarbonate solution. The loaded beads were
then surrounded by a semi permeable membrane to avoid sudden loss of CO2. Upon
coming in contact with gastric contents an exchange of chloride and bicarbonate
ions took place that resulted in CO2 generation thereby carrying beads toward the top
of gastric contents and producing a floating layer of resin beads 25.
Figure 8: Pictorial Presentation of working Effervescent floating drug delivery
system based on Ion exchange resin.
iv) Raft-Forming Systems
In these systems, a gel-forming solution (e.g. sodium alginate solution
containing carbonates or bicarbonates) swells and forms a viscous cohesive gel
containing entrapped CO2 bubbles on contact with gastric fluid. Formulations also
typically contain antacids such as Aluminium hydroxide or calcium carbonate to
reduce gastric acidity. Because raft-forming systems produce a layer on the top of
gastric fluids, they are often used for Gastro esophageal reflux treatment as with
liquid Gaviscon 26.
Figure 9: Schematic illustration of the barrier formed by a raft-forming
system
v) Low Density Systems:
Gas-generating systems inevitably have a lag time before floating on the
stomach contents, during which the dosage form may undergo premature evacuation
through the pyloric sphincter. Low-density systems (<1g/cm3) with immediate
buoyancy have therefore been developed. They are made of low-density materials,
entrapping oil or air. Most are multiple unit systems, and are also called
‘‘microballoons’’ because of the low-density core. Generally, techniques used to
prepare hollow microspheres involve simple solvent evaporation or solvent diffusion
methods. Polycarbonate, Eudragits, cellulose acetate, calcium alginate, agar and low
methoxylated pectin are commonly used as polymers. Buoyancy and drug release
are dependent on quantity of polymer, the plasticizer–polymer ratio and the solvent
used 27.
Figure 10: a) Microballoons (b) Foam-particles
B. Volatile liquid / Vacuum containing systems
These include the incorporation of matrix containing portion of liquid, which
produce gas that evaporates at body temperature 10.
i) Intra-gastric Floating Gastrointestinal Drug Delivery System
These systems can be made to float in the stomach because of floatation
chamber, which may be a vacuum or filled with air or a harmless gas, while drug
reservoir is encapsulated inside a micro-porous compartment.
Figure 11: Intra gastric floating Gastrointestinal Drug Delivery Device
ii) Inflatable Gastrointestinal Delivery Systems
In these systems an inflatable chamber is incorporated, which contains liquid
ether that gasifies at body temperature to cause the chamber to inflate in the
stomach. These systems are fabricated by loading the inflatable chamber with a drug
reservoir, which can be a drug impregnated polymeric matrix, encapsulated in a
gelatine capsule28.
Figure 12: Inflatable gastrointestinal delivery system
iii)  Intragastric Osmotically Controlled Drug Delivery System
It is comprised of an osmotic pressure controlled drug delivery device and an
inflatable floating support in a bio-erodible capsule. In the stomach the capsule
quickly disintegrates to release the intra-gastric osmotically controlled drug delivery
device. The inflatable supports inside forms a deformable hollow polymeric bag that
contains a liquid that gasify at body temperature to inflate the bag. The osmotic
controlled drug delivery device consists of two components – drug reservoir
compartment and osmotically active compartment 29.
Figure13: Intragastric Osmotically Controlled Drug DeliverySystem
2) Non-Effervescent FDDS
Non-effervescent floating drug delivery systems use a gel-forming or highly
swellable cellulose type hydrocolloids, polysaccharides or matrix forming polymers.
The formulation method includes the intimate mixing of drug with a gel forming
hydrocolloid. After oral administration this dosage form swell in   contact with
gastric fluids and attains a bulk density <1. The air entrapped with in the swollen
matrix imports buoyancy to these dosage forms. The swollen gel like structure acts
as a reservoir and allows sustained release of drug through the gelatinous mass..
Excipients used most commonly in these systems include Hydroxypropyl
methylcellulose (HPMC), Polyacrylates, Polyvinyl acetate, Carbopol, Agar, Sodium
alginate, Calcium chloride, Polyethylene oxide and Polycarbonates30.
A. Hydro Dynamically Balanced system;
These are single-unit dosage form, containing one or more gel-forming
Hydrophilic polymers. Hydroxypropylmethylcellulose (HPMC), Hydroxy ethyl
cellulose (HEC), Hydroxyl propyl cellulose (HPC), Sodium carboxy methyl
cellulose (NaCMC), polycarbophil, polyacrylate, polystyrene, agar, carrageenans
and alginic acid are also used. The polymer is mixed with drugs and usually
administered in a gelatin capsule. The capsule rapidly dissolves in the gastric fluid,
and hydration and swelling of the surface polymer produces a floating mass. Drug
release is controlled by the formation of a hydrated boundary at the surface.
Continuous erosion of the surface allows water penetration to the inner layers,
maintaining surface hydration and buoyancy 31.
Figure14: Working principle of Hydro Dynamically Balanced system
1. Single Layer Floating Tablets are formulated by intimate mixing of drug with a
gel-forming hydrocolloid, which swells in contact with gastric fluid and maintains
bulk density of less than unity.
2. A bi-layer tablet contain two layer one immediate release layer which releases
initial dose from system while the another sustained release layer absorbs gastric
fluid, forming an impermeable colloidal gel barrier on its surface, and maintain a
bulk density of less than unity and thereby it remains buoyant in the stomach.
B. Alginate Beads
Multi-unit floating dosage forms were developed from freeze-dried calcium
alginate. Spherical beads of approximately 2.5 mm diameter can be prepared by
dropping sodium alginate solution into aqueous solution of calcium chloride,
causing precipitation of calcium alginate leading to formation of porous system,
which can maintain a floating force for over 12 hours. When compared with solid
beads, which gave a short residence time of 1 hour, and these floating beads gave a
prolonged residence time of more than 5.5 hours 32.
III) Super porous hydrogel system
These swellable systems differ sufficiently from the conventional types to
warrant separate classification. These are used to improve gastric retention time
(GRT) super porous hydrogels have a average pore size >100 micro miter, swell to
equilibrium size within a minute due to rapid water uptake by capillary wetting
through numerous interconnected open pores (klusner2003). They swell to a large
size (swelling ratio: 100 or more) and are intended to have sufficient mechanical
strength to withstand pressure by gastric contraction. This is advised by co-
formulation of hydrophilic particulate material33.
Figure 15: Schematic Representation Super porus hydrogel
IV) Expandable, unfoldable and swellable systems
A dosage form in the stomach will withstand gastric transit if it bigger than
pyloric sphincter. However, the dosage form must be small enough to be swallowed,
and must not cause gastric obstruction either singly or by accumulation. The
configurations  required to develop an expandable system to prolong gastric
retention time (GRT) are
1) A small configuration for oral intake,
2) An expanded gastro retentive form, and
3) A final small form enabling evacuation following drug release from the device.
Unfoldable systems are made of biodegradable polymers and are available in
different geometric forms like tetrahedron, ring or planner membrane of bioerodible
polymer compressed within a capsule which extends in the stomach11.
Swellable systems are also retained in the gastro intestinal tract (GIT) due to their
mechanical properties. The swelling is usually results from osmotic absorption of
water.
Figure 16:  Different geometric forms of unfoldable systems
Drawbacks: Storage of much easily hydrolysable, biodegradable polymers
relatively short-lived, large single-unit expandable drug delivery dosage forms may
cause brief obstruction, intestinal adhesion and gastropathy .
V) Bio/Muco-Adhesive Systems
These are used to enhance drug absorption in a site-specific manner. In this
approach, bio adhesive polymers are used and they can adhere to the epithelial
surface in the stomach. Thus, they improve the prolongation of gastric retention. The
basis of adhesion is, the dosage form can stick to the mucosal surface by different
mechanism. Materials used for bioadhesion are poly acrylic acid, chitosan,
cholestyramine, sodium alginate, hydroxypropyl methylcellulose (HPMC),
sucralfate, tragacanth, dextrin, polyethylene glycol (PEG) and polylactic acids etc.
Draw back: Rapid turnover of mucous in the gastrointestinal tract (GIT).
Figure17: Schematic Representation of Bioadhesive microspheres
VI) Magnetic Systems:
This approach is used   to enhance the gastric retention time (GRT), and is based on
the simple principle that the dosage form contains a small internal magnet, and a
magnet placed on the abdomen over the position of the stomach. Although magnetic
system seems to work, the external magnet must be positioned with a degree of
precision that might compromise patient compliance34.
DISEASE PROFILE
INTRODUCTION :
Epilepsy was one of the first brain disorders to be described. It was
mentioned in ancient Babylon more than 3,000 years ago. The strange behavior
caused by some seizures has contributed through the ages to many superstitions and
prejudices. The word epilepsy is derived from the Greek word for "attack."
However, in 400 B.C., the early physician Hippocrates suggested that epilepsy was a
disorder of the brain -- and we now know that he was right35.
More than 2 million people in the United States -- about 1 in 100
have experienced an unprovoked seizure or been diagnosed with epilepsy. For about
80 percent of those diagnosed with epilepsy, seizures can be controlled with modern
medicines and surgical techniques36. However, about 25 to 30 percent of people with
epilepsy will continue to experience seizures even with the best available treatment.
Epilepsy :
Epilepsy is a brain disorder in which clusters of nerve cells, or
neurons, in the brain sometimes signal abnormally. Neurons normally generate
electrochemical impulses that act on other neurons, glands, and muscles to produce
human thoughts, feelings, and actions. In epilepsy, the normal pattern of neuronal
activity becomes disturbed, causing strange sensations, emotions, and behavior, or
sometimes convulsions, muscle spasms, and loss of consciousness37. During a
seizure, neurons may fire as many as 500 times a second, much faster than normal.
In some people, this happens only occasionally; for others, it may happen up to
hundreds of times a day.
The risk of premature death in people with epilepsy is 2-3 times
higher than the general population. The exact cause of the increased risk is not
known in most cases i.e. the cause of sudden unexpected death in some patients38.
However, some deaths are related to the circumstances around a seizure such as a
serious accident during a seizure.
CLASSIFICATION OF EPILEPTIC SEIZURES
Epilepsy can broadly be divided into two categories: idiopathic where
there is no known cause, and secondary seizures where there is known cause.
Seizures can be either generalized or partial (or focal). In generalized seizures, both
halves of the brain are simultaneously affected. In partial seizures, the abnormal
electrical discharge starts from a focus in one side of the brain. Later, this may
spread to the other side. This spread is called secondary generalization.
Generalized Seizures
In generalized seizures, patients suddenly stop what they are doing,
the eyes and head turn to one side and the body becomes stiff. This is usually
followed by several jerks of the hands and legs, groaning and frothing from the
mouth39.Generalized seizures consist of many different seizure types, of which the
primary generalized tonic-clonic seizure (GTCS) is the most common.
Tonic-clonic seizure
In a generalized tonic -clonic seizure the patient loses consciousness,
falls down, sometimes with a scream, and develops a generalized stiffness40.
Breathing stops, as all the muscles of the trunk are in spasm, the head is retracted,
the arms flexed and the legs extended. After a while, this tonic phase is followed by
the clonic phase, when the muscles alternately contract and relax, resulting in clonic
movements.Either the tonic phase or the clonic phase can predominate in the
seizureGeneralized tonic -clonic seizures can also occur due to secondary
generalization in partial epilepsies7.
Clonic seizures
These seizures are generalized seizures, where the tonic component is
not present, only repetitive clonic jerks (clonic jerks are repetitive rhythmic flexing
and stretching of limbs). When the frequency of jerks diminishes the amplitude of
the jerks does not diminish.
Tonic seizures
Tonic seizures are sudden sustained muscle contractions, fixing the
limbs in some strained position. There is immediate loss of consciousness. Often
there is deviation of eyes and head towards one side, sometimes rotation of the
whole body.
Absence seizures
These are short periods of loss of consciousness lasting only a few
seconds (not more than half a minute). They are of sudden onset, there are usually
no, or only minimal motor manifestations. There is a blank stare, brief upward
rotation of the eyes and an interruption of ongoing activity. The child is
unresponsive when spoken to. It is suddenly over, and the child continues what he
was doing before the seizure. People are unaware that these absences are epileptic
seizures41. Absences are easily provoked by hyperventilation.
Myoclonic seizures
These seizures consist of sudden, brief, shock-like muscle contractions,
either occurring in one limb, or more widespread and bilateral. They may be single
jerks, or jerks repeated over longer periods. They are often seen in combination with
other seizure types occurring in special epileptic syndromes.
Infantile spasms
Patients have flexor spasms of the head, bending of the knees and
flexion with abduction of the arms. They occur in the first year of life, and are very
difficult to treat.
Partial Seizures
Partial seizures are divided into two groups, simple partial seizures
where consciousness is maintained and complex partial seizures where there is an
impairment of consciousness.
Simple partial seizures
In simple partial seizures, some patients may experience either motor
or sensory phenomena. Such seizures arise from a specific area of the brain, with the
patient being fully or partly aware of the event. In motor seizures, the focus is in the
primary motor cortex. The psychic symptoms may consist of changes in mood,
memory, or thought . May be distorted perceptions or problems with language.
Structured hallucinations could occur. These simple partial seizures are usually only
recognized as epileptic seizures when they develop into generalized seizures42.
Complex partial seizures
Here the patient has impaired consciousness, but not complete loss of
consciousness. He is slightly aware of what is going on, but he cannot respond to
anything, neither can he change his behaviour during an attack. The seizure usually
starts with an aura which can be of many types such as, a strange feeling in the
stomach rising up to the throat and head, or a sensation of light, smell, sound or taste
or with changes in perception.After the attack, there is complete amnesia regarding
the attack.43
SYMPTOMS
Symptoms vary from person to person. Some people may have simple
staring spells, while others have violent shaking and loss of alertness. The type of
seizure depends on the part of the brain affected and cause of epilepsy44.
Most of the time, the seizure is similar to the previous one. Some people
with epilepsy have a strange sensation (such as tingling, smelling an odor that isn't
actually there, or emotional changes) before each seizure.45
DIAGNOSIS OF EPILEPSY
It is essential that patients with episodes such as described above be
accompanied by a witness who can describe the episodes in detail. More often than
not, epilepsy can be diagnosed on the basis of reports of patients and eyewitnesses.
No laboratory test can replace a clear description provided by the eyewitness.46
Those who develop epilepsy for the first time require investigations to identify the
underlying cause. These investigations include EEG, and imaging tests such as CT
scan or MRI of the brain.
Treatment
Treatment for epilepsy may involve surgery or medication.If epilepsy seizures are
due to a tumor, abnormal blood vessels, or bleeding in the brain, surgery to treat
these disorders may make the seizures stop47.
Medication to prevent seizures, called anticonvulsants, may reduce the number of
future seizures.
 Your dosage may need to be changed from time to time. You may need
regular blood tests to check for side effects.
 Always take your medication on time and as directed. Missing a dose can
cause you to have a seizure. Never not stop taking or change
medications without talking to your doctor first.
 Many epilepsy medications cause birth defects48. Women wishing to
become pregnant should tell the doctor in advance in order to adjust
medications.
Epilepsy that does not get better after two or three anti-seizure drugs have been tried
is called "medically refractory epilepsy."
 Surgery to remove the abnormal brain cells causing the seizures may be
helpful for some patients.
 Surgery to place a vagus nerve stimulator (VNS) may be recommended.
This device is similiar to a heart pacemaker. It can help reduce the
number of seizures.
Prevention
Generally, there is no known way to prevent epilepsy. However, proper
diet and sleep, and staying away from illegal drugs and alcohol, may decrease the
likelihood of triggering seizures in people with epilepsy.Reduce the risk of head
injury by wearing helmets during risky activities; this can help lessen the chance of
developing epilepsy49.
Persons with uncontrolled seizures should not drive. Each state has a
different law that determines which people with a history of seizures are allowed to
drive50. If you have uncontrolled seizures, you should also avoid activities where
loss of awareness would cause great danger.
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C. Sharon Kumar et al.,51 prepared and characterized the floating microspheres of
gabapentin by using the solvent evaporation method. The prepared floating
gabapentin microspheres were evaluated for different evaluation parameters such as
percentage yield, particle size determination, drug content determination,
Encapsulation efficiency, In-Vitro buoyancy, in-vitro drug release. The in vitro drug
release revealed that batch C was having 75% cumulative release at the end of 12 th
hour when compared with batch A & B ,due to increase in polymer concentration as
seen in formulation C (1:3). The release kinetics of Gabapentin followed Supercase
II transport diffusion.
Ferdous et.al.,52 developed floating tablets of theophylline using methocel K4M.
Sodium bicarbonate and citric acid were incorporated as gas generating agents. It
has been observed that in all cases increase of the amount of floating agent caused a
decrease of the floating lag time. Increase of theophylline load showed an increase
of the floating lag time, which was independent of floating agent content. The
release mechanisms were explored and explained with kinetic models. Kinetic
modeling of dissolution profiles revealed that the drug release mechanism could
range from diffusion controlled to case II transport, which was mainly dependent on
presence of relative amount of theophylline, polymer and floating agent.
Shailesh T. Prajapatiet al., 53 developed the Floating matrix tablets of
Domperidone using PEO WSR 303, HPMC and sodium bicarbonate by simplex
lattice design. Tablets were evaluated for in vitro floating ability and drug release
study. It was observed that as the PEO increased, release rate constant decreased.
Mechanism of drug release was anomalous type and dependent upon proportion of
HPMC and PEO. It was observed that independent factors had significant
contribution on all dependent variables.
Md. Mofizur Rahman et al.,54 evaluated the effect of hydrophilic polymers on the
release profile of drug from matrix system. Matrix tablets of salbutamol sulphate
were prepared by direct compression process using methocel K100M CR polymer.
Release kinetics of salbutamol sulphate from these sustained release matrices in
distilled water using USP paddle method with  for 8 hours were studied. Higher
polymer content (70%) in the matrix decreased the rate of the drug due to increased
tortuosity and decreased porosity. At lower polymeric level (30%), the rate of drug
release was elevated. The release mechanism was explored and explained with zero
order, first order, Higuchi and Korsmeyer equations. The results generated in this
study showed that the profile and kinetics of drug release were functions of polymer
type, polymer level and physico-chemical properties of the drug.
Rakesh Patel, Ashok Baria55, prepared a sustained release matrix tablet of
Theophylline  and different grades of hydroxypropyl methyl cellulose were
evaluated for gel forming properties.. The amounts of HPMC K-4M (X1) and
HPMC K-100M (X2) were selected as independent variables. Cumulative % release
of drug for 1st hour and 8th hour were selected as dependent variables.The results of
the full factorial design indicated that a low amount of HPMC K-100M and a high
amount of HPMC K-4M favors sustained release of Theophylline from matrix
tablet. Accelerated stability study was also performed for three months indicated that
optimized formulation was stable. Finally, process optimization was carried out to
optimize the process parameters like kneading time, mixing time, thickness of the
tablet and lubrication time.
R. Gendle et al.,56 developed sustained release tablets of highly water soluble
Tramadol HCl using polymers (HPMC K100M, HPMC K15M, HPMC K 4M) as
suitable hydrophilic matrix system. Sustained release tablet of Tramadol HCl (dose
50mg) were produced by wet granulation method. After the evaluation of physical
characteristics of tablets. The dissolution test was performed in 0.1 N HCl for two
hr. and phosphate buffer pH 6.8 for ten hr. The release profile remains unchanged
after three months storage of tablets. The best fit release kinetics was achieved with
the zero order plot followed by the Higuchi and Korsmyer and Peppas equation. The
data obtained proved that the formulations are useful for a sustained release of
Tramadol HCl due to the percentage released after 12 hr. is nearly to 100%.
P.N.Kendre et al.,57 developed single unit controlled delivery system of
Theophylline and was formulated as floating matrix tablet by direct compression
method using gas generating agent (sodium bicarbonate) and various viscosity
grades of hydrophilic polymers (HPMC K15M, K4M; HPC and Carbapol 934P).
The tablets swelled and eroded upon contact with release medium (0.1 N HCl) at 37
0C. The release rate could efficiently be modified by varying the matrix forming
polymer, the use of polymer blends and the addition of water soluble or water
insoluble fillers (such as dicalcium phosphate, lactose or mannitol). Fitting the in-
vitro drug release data to Korsmeyer equation indicated that diffusion along with
erosion could be the mechanism of drug release.
Ravala et al.,58 prepared Ranitidine hydrochloride floating matrix tablets based on
low density powder. The tablets were prepared by the direct compression technique,
using hydrophilic matrix polymers HPMC K4M, HPMC K15M, HPMC K100M,
sodium alginate, psyllum,sesbania gum, guar gum, and gum acacia, with or without
low density copolymer. . Incorporation of the highly porous low density copolymer
in the matrix tablets provides densities that are lower than the density of the release
medium. low density copolymer was sufficient to achieve proper in vitro floating
behavior for at least 8 h. Unlike most conventional floating systems, these tablets
floated almost immediately upon contact with the release medium.
Jaimini and Tanwar 59 prepared a gastro retentive drug delivery system of
Famotidine employing two different grades of methocel K100 and methocel K15M
by effervescent technique; these grades of methocel were evaluated for their gel
forming properties. Sodium bicarbonate, citric acid were incorporated as a gas-
generating agents. . Decrease in the citric acid level increased the floating lag time
but tablets floated for longer duration. The tablets with methocel K100 were found
to float for longer duration as compared with formulations containing methocel
K15M. The drug release from the tablets was sufficiently sustained and non-Fickian
transport of the drug from tablets was confirmed.
Sandra Strübing et al.,60 developed floating kollidon® SR matrix tablets
containing propranolol.Tablet floating started immediately and continued for 24 h.
Floating strength was related to Kollidon® SR level with improved floating
characteristics for samples with a high polymer/drug ratio. The influence of the
polymer content on swelling characteristics was found to be only marginal.
Furthermore, the new method of benchtop MRI was introduced to study the water
diffusion and swelling behaviour non-invasively and continuously.
M.Harris Shoaib et al.,61 developed a once-daily sustained release matrix tablet of
ibuprofen using hydroxypropyl methylcellulose (HPMC) as release controlling
factor and to evaluate drug release parameters as per various release kinetic models.
In order to achieve required sustained release profile tablets were directly
compressed using Avicel pH 101 and Magnesium stearate. The drug release data fit
well to the Higuchi expression. Drug release mechanism was found as a complex
mixture of diffusion, swelling and erosion.
Pare A et al.,62 developed amlodipine besylate effervescent floating tablets in ten
different formulations (F1 to F10) by employing different grades of polymers and
effervescent agents such as sodium bicarbonate and citric acid.. F10 formulation
showed maximum floating time of 24 hours and gave slow and maximum drug
release of Amlodipine besylate spread over 24 hours and whereas Amlodipine
besylate released from marketed tablet was rapid and maximum within 12 hours.
Patel Amit et al.,63 prepared  floating drug delivery system of famotidine. Six
formulations were prepared containing gel-forming agent (HPMC K4M) and
retardant (Na-CMC) in different ratio and it was found that gas generating agent
(NaHCO3) reacts with HCl and liberates CO2 which creates pores in tablet and
elevates swelling and maintains buoyancy. The prepared tablets were evaluated for
content uniformity, hardness, friability, buoyancy, swelling index and in-vitro
dissolution studies. Further selected formulation was subjected for short term
stability studies for one and two month at temperature of 25°c and 40°c respectively
Shreeraj H. Shah et al.,64 developed a gastric floating drug delivery system
(GFDDS) containing Levofloxacin against the H.pylori infection.Stability study was
also performed after storage at 40°C/75% RH for three months.The batch containing
combination of HPMC K4M, HPMC K100M and Carbopol 974P (i.e. L12) showed
total floating lag time more than 24 hrs. The batch L12 showed the highest swelling
index among all the prepared batches (i.e. 95%). The batch L12 was chosen as the
optimized batch since it was also stable for three months during stability study.
Senthilkumar et al., 65 prepared and evaluated floating microsphere using
Rabeprazole sodium (RS) as a model drug for prolongation of the gastric retention
time. The microspheres were prepared by the solvent evaporation method using
different polymers like HPMC and MC ,to achieve an extended retention in the
upper gastrointestinal tract, which may result in enhanced absorption and there by
improved bioavailability. HPMC Containing microspheres showed a desirable high
drug content, flow property, buoyancy, adequate release characteristics hence,
formulations prepared by such polymer are suitable for development of gastro
retentive dosage forms.
Reddy Sunil et al.,66 developed bilayered tablets containing Glimepride for
immediate release using sodium starch glycolate as super disintegrant and
Metformin hydrochloride (HCl) for sustained release by using Hydroxyl propyl
methyl cellulose (HPMC K 4M) and Sodium Carboxy Methyl cellulose (SCMC) as
the matrix forming polymer, and PVPK-30 as binder... The polymer (HPMC K4M,
SCMC) and binder PVPK-30 had significant effect on the release of Metformin HCl
matrix tablets (F5). Thus formulated bilayer tablets provided immediate release of
Glimepride and Metformin HCl as sustained release over a period of 8 hours.
Stability studies and FT-IR studies clearly indicated that there is no drug –polymer
interaction.
Baumgartner S et al.,67 developed floating matrix tablets containing
Hydroxypropyl Methyl Cellulose , which after oral administration are designed to
prolong the gastric residence time , increase the bioavailability and diminish the side
effects of irrititating drugs.The importance of the composition optimization , the
formulation aspect and characterization of the tablets were examined.The
investigation showed that the talet composition and mechanical strength have great
influence on the floating and drug release properties of the tablets. They concluded
that the drug release from the tablets followed non-Fickian transport.
Vishal G. Karkhile et al.,68 prepared floating tablet of Furosemide  by direct
compression technique. Furosemide was chosen as model drug because it is slightly
soluble in water and poorly absorb from lower intestine. PEG-6000 is used as
complexing   agent for increasing solubility of Furosemide in water.
Hydroxypropylmethylcellulose, sodium bicarbonate and carbapole were used as
Matrixing agent gas generating agent and floating enhancers respectively. Further,
tablets were evaluated for in vitro release characteristic for 8 hrs. The data of in-vitro
dissolution study shows that the zero order plots were found to be fairly linear as
indicated by their high regression value (R2=0.9772 to 0.9911). To confirm the
exact mechanism of drug release from different formulation, the data was fitted to
Korsmeyer Peppas equation.
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AIM AND OBJECTIVE
 The majority of the drugs are absorbed in the upper part of the small
intestine.
 Gabapentin is an anti epileptic drug and also used now-a-days to treat
neuropathic pains. It is rapidly absorbed from GIT and plasma half life is
about 5-7 hours. Its short biological half life and once daily administration of
conventional tablet, which maintains study state of concentration was
difficult, to overcome this problem the present work is proposed for the
sustained release effervescent floating dosage form of Gabapentin.
 Conventional dosage forms reside in stomach and intestine for only short
period.  So there is a need of dosage form that increases residence time of
drugs in absorption site.
 Gastroretentive dosage forms are used to increase residence time of drugs.
Among the gastroretentive systems effervescent floating tablets have more
advantages.
 The aim of the present work is to formulate gastroretentive dosage form of
gabapentin by effervescent floating tablet technique by using various
polymers.
 One of the purpose of this formulation was to maintain in vitro buoyancy as
well as duration of floating stable for at least 12 hours and invitro dissolution
study.
 To study the effect of polymer grade or viscosity: In the present investigation
Hydroxypropyl Methylcellulose K100M, Sodium Carboxy Methyl Cellulose,
Polyethylene Oxide, were used to increase duration of floating and release
rate .
 Rate of drug release and mechanism of drug release from the designed
tablets were evaluated.
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To achieve the above objectives the experimental work was framed as below
Phase-I:
1. Pre-formulation study of pure drug gabapentin
2. Compatibility study
i) Fourier transform infrared spectroscopy (FT-IR)
Phase-II:
1) Formulation of effervescent floating tablets of  Gabapentin.
A) Determination of effect of sodium bicarbonate  on floating lag time
B) Formulation of Gabapentin (600 mg) effervescent floating tablets with
different concentrations of HPMC K100M, Sodium CMC , PEO.
2) Evaluation of precompression blend for various parameters like Angle of
Repose, Bulk density, Tapped density and Carr’s index.
3) Evaluation of effervescent floating  tablets of  Gabapentin
A) To determine floating lag time and total buoyancy time.
B) To evaluate prepared matrix tablets for various physical parameters like
Weight variation, Thickness, Hardness and Friability.
C) Determination of in vitro drug release from the formulations in 0.1N
HCl for 12 hours.
D) Determination of percentage swelling of all formulations.
E) To determine content uniformity of effervescent floating tablets.
F) In vitro release data was fitted into various kinetic models for
suggesting the suitable mechanism of drug release.
4) Selection of the best batch of tablets based on the in vitro release kinetic data.
5) Determination of drug-excipients interaction of optimized formulations.
6) Accelerated stability study of the optimized formulation.
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DRUG PROFILE
Drug information69
Generic name : Gabapentin
Trade name : Neurotin
Chemical name : 2-[1-(amionmethyl) cyclohexyl] acetic acid
Empirical formula : C9H17NO2
Molecular weight : 171.24
Structure:
Physico chemical profile:
Description : White or partially white amorphous powder
Melting point : 162-166 C
Solubility : Freely soluble in water, acidic, alkaline solutions
Partition co-efficient : log p equal to 1.4
Pharmaceutical profile:
Dosage forms and dose
Tablets 100,300,400,600,800 mg Capsules –100,300,400mg
Pharmacopoeial status
Official in USP and IP
Analytical profile:
Chromatographically analyzed by HPLC at 210 nm.
Pharmacokinetic profile:
Oral absorption : 60% .Food has slight effect on the rate and
absorption (14% increase in auc)
Plasma half life : 5-7 hours
Volume of distribution : 58±6 L
Protein binding : less then 3%
Metabolism : not apparently metabolized
Clearance : 140 ml/min
Excretion : renal
Pharmacological profile : Antiepileptic
EXCIPIENT PROFILE
HYDROXYPROPYL METHYLCELLULOSE70
Non-proprietary
names
: Hydroxypropyl methylcellulose
Chemical name : Cellulose, 2-hydroxypropylmethylether
Molecular Weight : Approx. 86,000 g/mol
Types and grades : Various grades of HPMC, official in USP, BPC, IP,
are frequently employed as polymer for controlled
drug release. For BPC/IP grades the name is followed
by a number indicating the apparent viscosity of a 2%
w/v solution in mill Pascal seconds at 20C. For USP
grade HPMC, the name is followed by a four-digit
numbers. The first two digits refer to the approximate
content of the methoxy (-OCH3) groups and the second
digit refers to the approximate content of the
hydroxypropoxy group (-CH2CHOCH3) in percent,
calculated on dry basis (105oc for two hours).
Structure of HPMC
Physiochemical properties
Apparent density : 0.25-0.70 g/cm3
Particle size :  95% through 40 mesh
Percentage moisture : 3% (maximum)
Specific gravity : Approximately 1.3
Surface activity : Provides some surfactancy in solutions. Surface
tensions for such solution range from 42-56
dynes/cm
Gel formation : Undergoes a reversible transformation from sol to
gel upon heating and cooling, respectively.
Glass transition : 155oC
Solubility : Soluble in cold water, forming a viscous colloidal
solution, practically insoluble in hot water, acetone
and toluene, insoluble in alcohol, ether and
chloroform, but soluble in mixture of methyl alcohol
and methylene chloride. Certain grades are soluble in
aqueous acetone, mixture of methylene chloride and
isopropyl alcohol and other organic solvents.
Stability : Very stable in dry conditions. Solutions are stable at
pH 3.0-11.0. Aqueous solutions are liable to be
affected by microorganisms.
Storage : To be stored in a tight container and in a cool place
Safety : Human and animal feeding studies have shown
HPMC to be safe.
Table 4: Methocel grades, their viscosities and application
Grade Viscosity Application
E5 5 Film coating, Granulating agent
E15 15 Film coating, Granulating agent, Suspending agent
E50 50 Film coating, Granulating agent
E4M 4000 Sustained release, Medicated gel, Thickening agent
E4MCR 4000 Sustained release
E10M 10,000 Sustained release
E10MCR 10,000 Sustained release
F4M 4000 Eye drops, Suspending agent
K4M 4000 Sustained release, Suspending agent
K15M 15,000 Sustained release
K15MCR 15,000 Sustained release
K100M 100,000 Sustained release
K100MCR 100,000 Sustained release
SODIUM BICARBONATE71
Nonproprietary
Names
: BP: Sodium bicarbonate
JP: Sodium bicarbonate
PhEur: Natrii hydrogenocarbonas
USP: Sodium bicarbonate
Synonyms : Baking soda; E500; Effer-Soda; monosodium
carbonate; Sal de Vichy; sodium acid carbonate;
sodium hydrogen carbonate.
Description : Sodium bicarbonate occurs as an odorless, white,
crystalline powder with a saline, slightly alkaline
taste. The crystal structure is monoclinic prisms.
Grades with different particle sizes, from a fine
powder to free-flowing uniform granules, are
commercially available.
Chemical Name : Carbonic acid monosodium salt
Empirical Formula : NaHCO3
Molecular Weight : 84.01 g/mol
Structural Formula : NaHCO3
Melting point : 270°C (with decomposition)
Functional Category : Alkalizing agent; therapeutic agent.
Applications : Sodium bicarbonate is generally used in
pharmaceutical formulations as a source of carbon
dioxide in effervescent tablets and granules. It is also
widely used to produce or maintain an alkaline pH in
a preparation. Sodium bicarbonate is also used in
tablet formulations to buffer drug molecules that are
weak acids, thereby increasing the rate of tablet
dissolution and reducing gastric irritation.
Stability : When heated to about 50°C, sodium bicarbonate
begins to dissociate into carbon dioxide, sodium
carbonate, and water; on heating to 250–300°C, for a
short time, sodium bicarbonate is completely
converted into anhydrous sodium carbonate.
Storage Conditions : Stored in a well-closed container in a cool, dry
place.
Table 5:  Uses of Sodium bicarbonate
Use Concentration (%)
Buffer in tablets 10–40
Effervescent tablets 25–50
Isotonic injection/infusion 1.39
POLYETHYLENEOXIDE72
Non proprietary name : USPNF : Polyethyleneoxide
Synonyms : Polyox ; polyoxirane ; polyoxyethylene
Chemical name : Polyethylene oxide
Empirical formula : CH2CH2O
Description : White to off white, free flowing powder,
slight ammonical odour.
Structural formula : (CH2CH2O)n
Functional category : Mucoadhesive , thickening agent,
tablet binder.
Melting point : 65 – 70oC
Applications : Polyethylene oxide can be used as a tabler binder
at a concentration of 5-85%. It has been shown to
be an excellent mucoadhesive polymer. The film
form of PEO demonstrate good lubricity when
wet.It also acts as a radiation crosslinked in
solution to poduce a hydrogel that can be used in
wound care application.
Stability and storage
conditions : Store in tightly sealed containetr in a cool, dry
place. Avoid exposure to high temperatre since
this can result in reduction of viscosity.
CARBOXYMETHYLCELLULOSE SODIUM73
Nonpropietary names : BP: Carmellose sodium
JP : Carmellose sodium
PhEur : Carmellose natricum
USP : Carboxymethylcellulose sodium
Synonyms : Akucell, aquasorb, blanose, cellulose gum, SCMC
finnifix, tylose CB, nymcel, sodium cellulose
glycolate, sodium carboxymethylcellulose.
Chemical name and CAS : Cellulose, carboxymethyl ether, sodium salt
Registry number [9004-32-4]
Emperical formula and : The USP 28 describes carboxymethylcellulose
Molecular weight sodium as the sodium salt of polycarboxymethyl
ether of cellulose. Typical molecular weight is
90000-7000000 g/mol.
Functional category : Coating agent, stabilizing agent, suspending agent,
tablet and capsule disintegrant, tablet binder,
viscosity  increasing agent, wet absorbing agent.
Description : Carboxymethylcellulose sodium occurs as a
White to almost white, odorless, granular powder.
Melting point : Browns at approximately 227oC and chars at
Approximately 252oC.
Applications : Carboxymethylcellulose sodium is widely used in
oral and topical pharmaceutical formulations,
primarily for its viscosity increasing property. It
may also be used as a tablet binder and
disintegrant and to stabilize emulsions. higher
concentrations usually 3-6% of the medium
viscosity grade are used to produce gels that can
be used to produce gels that can be used as the
base for application and pastes. It is additionally
one of the main ingredient of self-adhesive
ostomy, wound care and dermatological patches
where it is used as muco adhesive and to absorb
wound exudates or transepidermal water and
sweat. This muco-adhesive property is used in
products designed to prevent post surgical tissue
adhesions. It is also used in cosmetics, toiletries,
surgical prosthetics and incontinence, personel
hygiene and food products.
Stability and storage : It is stable, though hygroscopic material. Under
Conditions high humidity, it can absorb a large quantity of
water. In tablets, this has been associated with
decrease in tablet hardeness and increase in
disintegration time. Aqueous solution are stable at
pH 2-10 ; precipitation can occur below pH 2..This
results in significant decrease in viscosity,
deterioration in the properties of solution prepared
from the sterilized material. Aqueous solution
stored for prolonged periods should contain an
antimicrobial preservative. Bulk material should
be stored in a well closed container in a cool, dry
place.
MICROCRYSTALLINE CELLULOSE74
Non proprietary names : BP : Microcrystalline cellulose
JP : Microcystalline cellulose
Ph Eur : Cellulose microcristallinum
USPNF : Microcrystalline cellulose
Synonyms : Cellulose gel, crystalline cellulose , fibrocel ,
tabalose.
Chemical name and CAS : Cellulose [9004-34-6]
Registry number
Emperical formula and : (C6H10O5)n ~ 3600
Molecular weight where n ~ 220
Functional category : Adsorbent, suspending agent, tablet and capsule
Diluents, tablet disintegrant.
Description : Microcrystalline cellulose is purified, partially
depolymerised cellulose that occurs as a white,
odourless tasteless, crystalline powder composed
of porous particles. It is commercially available in
different particle size and moisture grades that
have different properties and applications.
Melting point : Chars at 260-270o C
Applications : Microcrystalline cellulose is widely used in
pharmaceuticals, primarily as a binder / diluents
in oral tablets and capsule formulation where it is
used in both wet granulation and direct
compression process. In addition it also has some
lubrication and disintegrant properties that makes
it useful in tableting.
Stability and storage : It is stable through hygroscopic materials. The
Conditions bulk material should be stored in a well – closed
container in a cool, dry place.
COPOVIDONE75
Nonpropietary name : BP : Copovidone
PhEur : Copovidone
USP –NF :Copovidone
Synonyms : Acetylacid vinyl ester , plasidone S – 630,
PVP /VA copolymer , PVP/VA , polyvinylpyrr
-olidone – vinyl acetate copolymer.
Chemical name and CAS : Acetic acid ethynyl ester , polymer with
Registry number 1-ethynl-2-pyrrolidone [25086-89-9]
Empirical formula and : (C6H9NO)n (C4H6O2)m
Molecular formula
Functional category : Film-forming agent ; granulation aid; binder
Melting point : 140oC
Applications : Copovidone is used as a tablet binder, a
filmformer and as a part of the matrix material
used in controlled release formulation. In tableting,
copovidone can used as a binder for direct
compression and as a binder in wet granulation
copovidone is often added to coating solution as a
film-forming agent.  It provides good adhesion,
elasticity and hardnessand can be used as a
moisture barrier.
Description : Copovidone is a white to yellowish amorphous
powder. It is typically spray –dried with a
relatively fine particle size. It has a slight odour
and a faint taste.
Stability and storage : Copovidone is stable and shold be stored in a
Conditions well-closed container in a cool ,dry place.
AEROSIL76
Nonpropietary : BP : Colloidal anhydrous silica
JP : Light anhydrous silica acid
PhEur : Slica colloidal anhydrous
USP-NF : Colloidal silicon dioxide
Synonyms : Colloidal silica, fumed silica, fumed silicon
dioxide, hochdisperses silicum dioxid, SAS,
silicon dioxide colloidal.
Chemical name and : Silica [7631-86-9]
CAS Registry number
Emperical formula and : Sio2
Molecular weight : 60.08 g/mol
Functional category : Adsorbent, anticaking agent, emulsion stabilizer,
glidant, suspending agent, tablet disintegrant,
thermal stabilizer, viscosity increasing agent.
Application : It is widely used in pharmaceutical, cosmetics and
food products. Its small particles size and large
specific surface area give it desirable flow
characteristics that are exploited to improve the
flow property of dry powders in a number of
processes such as tableting and capsule filling. It is
also used to stabilize emulsions and as a
thixotropic thickening and suspending agent in
gels and semisolids preparation In aerosols, other
than those for inhalation, colloidal silicon dioxide
is used to promote particulate suspension,
eliminate hard settling and minimize the clogging
of spray nozzle. Colloidal is also used as a tablet
disintegrant and as an absorbent dispencing agent
for liquids in podwer. It is also used as an
adsorbent during the preparation of wax
microspheres as a thickening agent for topical
preparation has been used to aid the freeze drying
of nanoparticles and nanosphere suspensions.
Melting point : 1600oC
Description : It is a submicroscopic fumed silica with a particle
size of about 15 nm.  It is a light, loose,
bluishwhite coloured, odorless, tasteless,
amorphous powder.
Stability and storage : It is hygroscopic but adsorbs large quantities of
Conditions water without liquifing. When used in aqueous
system at a pH 0-7.5, colloidal silicon dioxide is
effective in increasing viscosity property of
colloidal silicon dioxide are reduced ; and at pH
greater than 10.7 this ability is lost entirely since
the silicate dioxide dissolves to form silicates.
Colloidal silicon dioxide powder should be stored
in a well closed container.
MAGNESIUM STEARATE77
Non proprietary name : BP: magnesium stearate,
JP: magnesium stearate, Pheur: magnesii
stearas, USPNF: magnesium stearate.
Synonyms : Magnesium octsdecanoate; octa decanoic
acid,magnesium salt; stearic acid, magnesium
salt
Chemical name and CAS
registry number
: Octadecanoic acid magnesium salt [557-04-0]
Functional category : Tablet and capsule lubricant
Application in
pharmaceutical formulation
or technology
: Magnesium stearate is widely used in
cosmetics, foods and in pharmaceutical
formulation. It is primarily used as a lubricant
in capsule and tablet manufacture.
Description : Magnesium stearate is a very fine, light white,
precipitated or milld, implantable powder of
low bulk density, having a faint odor of stearic
acid and a characteristic taste. The powder is
greesy to the touch and readily adheres to the
skin.
Melting range : 117-150oC (commercial samples); 126-130oC
(high purity magnesium stearate)
LACTOSE78:
Nonproprietary names : Lactose (BP), Lactose Monohydrate (PhEUR,
USP-NF).
Synonym : CapsuLac, GranuLac, Lactochem, lactosum
monohydricum, onohydrate, Pharmatose,
PrismaLac, SacheLac, SorboLac, pheroLac,
SuperTab 30GR, Tablettose.
Chemical Name and
CAS Registry Number : O-b-D-Galactopyranosyl-(1!4)-a-D-glucopyranose
monohydrate, [10039-26-6]
Emprical Formula and
molecular weight : Formula:C12H22O11·H2O.  MW: 360.31
Description : In solid state, lactose appears as various isomeric
forms, depending on the crystallization and drying
conditions, i.e. αlactose monohydrate, β-lactose
anhydrous, and α-lactose anhydrous. Lactose
occurs as white to off-white crystalline particles or
powder, it is odorless and slightly sweet-tasting.
pH : 5.5-8.9.(1%w/w aqueous solution at 25o)
Solubility : Insoluble in chloroform, ethanol, ether. Soluble in
water in ratio of 1 in 5.24.
Melting point : 201–2020C (for dehydrated a-lactose
monohydrate)
Moisture content : Lactose monohydrate contains normally has a
range of 4.5 – 5.5% w/w water content.
Functional Category : Dry powder inhaler carrier, lyophilization aid,
tablet binder, tablet and capsule diluent, tablet and
capsule filler.
Applications : Lactose is widely used as a filler and diluent in
tablets and capsules. Lactose is also used as a
diluent in dry-powder inhalation. Lactose is added
to freeze-dried solutions to increase plug size and
aid cohesion. Lactose is also used in combination
with sucrose to prepare sugar-coating solutions. It
may also be used in intravenous injections.
Lactose is also used in the manufacture of dry
powder formulations for use as aqueous film-
coating solutions or suspensions. Direct-
compression grades of lactose monohydrate are
available as spray-dried lactose and anhydrous
lactose.
Incompatibilities : A Millard-type condensation reaction is likely to
occur between lactose and compounds with a
primary amine group to form brown, or yellow-
brown-colored products. Lactose is also
incompatible with amino acids, amphetamines and
lisinopril.
Stability and
storage conditions : Mold growth may occur under humid conditions
(80% relative humidity and above). Lactose may
develop a brown coloration on storage, the
reaction being accelerated by warm, damp
conditions. Solutions show mutarotation. Lactose
should be stored in a well-closed container in a
cool, dry place.
Chapter VI
Materials and Methods
MATERIALS AND METHODS
MATERIALS:
Drug : Gabapentin was obtained from Torrent Pharmaceuticals, Ltd.
Table 6: List of materials
S.NO. MATERIALS SUPPLIER
1 Gabapentin Torrent  Pharmaceuticals, Ltd
2 HPMC K100M ISP,  Hyderabad
3 Sodium bicarbonate Merck Specialities Pvt. Ltd
4 Poly ethylene oxide Merck Specialities Pvt. Ltd
5 Sodium CMC ISP,  Hyderabad
6 Micro crystalline cellulose Dr. Reddy’s Lab ,Hyderabad
7 Poly vinyl pyrollidine ISP,  Hyderabad
8 Aerosil S.D Fine Chemicals, Mumbai
EQUIPMENTS :
Table 7:  Equipments used and their manufacturers
S.NO
INSTRUMENTS
MANUFACTURES/
SUPPLIERS
1 Electronic Balance ER-200A(AFCOSET)
2 Punching machine
RIMEK 10 station compression
machine
3 Hardness Tester Pfazer  [Ssi-62(B)]
4 Friability Test Apparatus Roche Friabilator
5 Tap density tester Electro lab
6 pH meter ELICO LI 120 PH Meter
7 Tablet Dissolution Tester
(USP П)
ELECTROLAB ( TDT-O8L)
8
HPLC
WATERS 2487 DUAL
ABSORBANCE DETECTOR.
9 FTIR Spectrophotometer BRUKER IR instrument
10 Mesh # 25, 40, 60 Retsec (ASLOO)
METHODOLOGY :
To formulate an intelligent formulation, the pre-formulation studies are
usually the quantitative assessment of chemical stability of drug as well as stability
in presence of other excipients for a formulation.
a) PREFORMULATION STUDIES:
Preformulation may be described as a phase of the research and development
process where the formulation scientist characterizes the physical, chemical and
mechanical properties of new drug substances, in order to develop stable, safe and
effective dosage forms. Ideally the preformulation phase begins early in the
discovery process such the appropriate physical, chemical data is available to aid the
selection of new chemical entities that enter the development process during this
evaluation possible interaction with various inert ingredients intended for use in final
dosage form are also considered in the present study79.
The following Preformulation studies were performed:
 Study of organoleptic properties
 Solubility analysis
 Melting point of drug
 Drug powder characterization
 Particle size analysis
 Physical compatibility studies
 Identification of drug-excipients compatibility study by FT-IR
Organoleptic properties:
Colour: a small quantity of pure gabapentin powder was taken in a  paper and
viewed in well illuminated place.
Taste and odour: Very less quantity of gabapentin was used to get taste with the
help of tongue as well as smelled to get the odour.
Loss on drying:
Determine on 1.000 g by drying in an oven at 100°C to 105°C for 3 hours.
Accurately weigh the substance to be tested.  If the sample is in the form of large
crystals, reduce the particle size to about 2 mm by quickly crushing.  Tare a glass
stopper, shallow weighing bottle that has been dried for 30 minutes under the same
conditions to be employed in the determination.  Put the sample in bottle, replace the
cover, and accurately weigh the bottle and the contents.  By gentle, sidewise
shaking, distribute the sample as evenly as practicable to a depth of about 5 mm.
Place the loaded bottle in the drying chamber.  Dry the sample at the specified
temperature from constant weight80. Upon opening the chamber, close the bottle
promptly, and allow it to come to room temperature in desiccators before weighing.
The difference between successive weights should not be more than 0.5mg.
The loss on drying is calculated by the formula:
(W2-W3)
% LOD = ----------------------------- X 100
(W2-W1)
Where,      W1 = Weight of empty weighing bottle
W2 = Weight of weighing bottle + sample
W3 = Weight of weighing bottle + dried sample
Solubility analysis81:
Solubility is important pre-formulation parameter because it affects the
dissolution of drug, bioavailability of drug.
Method: weigh appropriate quantity of drug and added to the suitable volume of
solvent.
Melting point:
The melting point of gabapentin was determined by capillary method, using
small quantity of gabapentin was taken and placed in apparatus and determined the
melting point and matched with standards82.
Drug powder characterization:
Angle of repose83: The frictional forces in a loose powder or granules can be
measured by angle of repose. This is themaximum angle possible between the
surface of a pile of powder or granules and the horizontal plane and is related to the
density, surface area and co-efficient of friction of the raw material.
Method: Angle of repose was determined by using funnel method. The height of the
funnel was adjusted in such a way that the tip of the funnel just touches the heap of
the blends. Accurately weighed blend is allowed to pass through the funnel freely on
the surface82. The height and diameter of the powder cone was measured and angle
of repose was calculated using the following equation.
Ө = tan-1 (h/r)
Where, h = height of heap, r = radius of heap, Ө = angle of repose.
Table-8: Limits:
Angle of repose Flow property
<25o Excellent
25-30 o Good
30-40 o Passable
>40 o Very poor
Bulk density: Bulk density is defined as the mass of the powder divided by the bulk
volume. Bulk density largely depends on particle shape, as the particle become more
spherical in shape, bulk density is increase. In addition as the granule size increases
bulk density decreases.
Method: weighed quantity of active powder ingredient (API) was transferred into
100 ml measuring cylinder without tapping during transfer. The volume occupied by
the API was measured. Bulk density was measured by using the formula
Bulk Density = Bulk Mass / Bulk Volume
Tapped density: Tapped density is achieved by mechanically tapping a measuring
cylinder containing a powder sample. After observing the initial volume, the
cylinder is mechanically tapped and volume readings are taken until little further
volume changes is observed the mechanical tapping is achieved by raising the
cylinder and allowing it to drop under its own weigh a specific distance. Device that
rotates device during tapping may be preferred to minimize any possible separation
of the mass during tapping down.
Cylinder dropping distance: 14± 2mm at a normal rate of 300 drops / minute.
Unless otherwise specified, tab the cylinder 500 times initially and measure the
tapped volume Va, the nearest graduated unit. Repeat the tapping an additional 750
times and measure the tapped volume, Vb, to the nearest graduated unit. If the
difference between the two volumes is less than 2%, Vb is the final tapped volume,
Vf. Repeat in increments of 1250 taps, as needed, unit the difference between
succeeding measurements is less than 2%. Calculate the tapped density, in gm per
ml, by the formula:
Tapped Density =
Vf
m
Where, m = initial weight of material in gm, Vf = volume of material after tapping.
Generally replicate determinations are desirable for the determination of this
property.
Measurement of Powder Compressibility:
The compressibility Index and Hausner Ratio are measures of the propensity
of a powder to be compressed. As such, they are measures of the relative importance
of inter particulate interactions. In a free flowing power, such interactions are
generally less and tapped densities will be closer in value. For poorer flowing
materials, there are frequently greater inter particle interactions, and a greater
difference between bulk and tapped densities will be observed. These differences are
reflected in the compressibility Index and the Hausner Ratio Calculated by the
formula:
Compressibility index: =
0
0 )(100
V
VfV 
Where, Vf = final tapped volume, Vo = initial un tapped volume.
Table : 9 Limits
S.no Compressibility index Flow
1 5-12 Free flow
2 12-16 Good flow
3 18-21 Fair
4 23-25 Poor
5 33-38 Very poor
6 >40 Extremely poor
Hausner Ratio: =
Vf
V0
Where, Vf = final tapped volume, Vo = initial un tapped volume.
Table-10: Limits:
S.No Hausner’ ratio Flow
1 1-1.2 Free flowing
2 1.2-1.6 Cohesive powder
Physical compatibility studies84:
In the tablet dosage form the drug is in intimate contact with one or more
excipients, the latter could affect the stability of the drug. Knowledge of drug
excipient interactions, therefore very useful to the formulator in selecting the
appropriate excipients.
Gabapentin was mixed well with the excipients according to the formula selected for
the tabletting and kept small portion of this mixed powder in cleaned and dried vials
in stability chamber at 40oC±2o C / 75±5RH and room temperature. Physical
observations have been carried out visually for 7 days.
a) COMPATIBILITY STUDIES:
One of the requirement for the selection of suitable excipients or carrier for
pharmaceutical formulation is its compatibility. Therefore in the present work a
study was carried out by using FTIR spectrometer to find out if, any possible
chemical interaction of Gabapentin with HPMC K100M , Sodium CMC, PEO.
Compatibility with polymers was confirmed by FTIR studies.
FOURIER TRANSFORMS INFRARED SPECTROMETRY (FTIR):
Compatibility study of drug with the excipients was determined by I.R.
Spectroscopy (FTIR) using Bruker spectrometer model85. The pellets were prepared
at high compaction pressure by using KBr and the ratio of sample to KBr is 1:200.
The pellets thus prepared were examined and the spectra of drug and other
ingredients in the formulations were compared with that of the original spectra.
c)PREPARATION OF STANDARD CALIBRATION CURVE OF
GABAPENTIN:
METHOD:
Gabapentin is estimated chromatogramically in HPLC at 210 nm.
PREPARATION OF PH 6.9 BUFFER SOLUTION86:
7gms of Potassium dihydrogen orthophosphate was weighed and taken in
1000 ml  beaker. It is been dissolved and diluted with 1000 ml of HPLC water. And
now this solution has been adjusted to PH 6.9 with KOH.
PREPARATION OF MOBILE PHASE:
940ml (94%) of above prepared buffer solution is been mixed up with 60 ml
(6%) of Acetonitrile HPLC and was degassed in ultrasonic water bath for 5 mins
and this solution is been filtered through 0.45µ filter under vacuum filtration
PREPARATION OF STANDARD DRUG SOLUTION:
STANDARD SOLUTION:
2 ml of stock solution is taken and this is made up to 20 ml with the mobile
phase. 100ppm concentration of solution is prepared. From these different dilutions
where prepared like 20ppm, 30ppm, 40ppm, 50ppm, 60ppm respectively with
mobile phase used as diluent’s solution. And peak areas of this solutions are been
taken at 210 nm in HPLC .
FORMULATION OF GABAPENTIN FLOATING TABLETS:
Table : 11: Ingredients used and their role
S.NO. MATERIALS CATEGORY
1 GABAPENTIN Active ingredient
2 SODIUM CMC Polymer
3 PEO Polymer
4 HPMC K100M Polymer
5 PVP Binder
6 MCC Disintegrant
7 LACTOSE Diluent
8 AEROSIL Glidant
9 SODIUMBICARBONATE Alkalizing agent
10 MAGNESIUM STERATE Lubricant
Formulation of gabapentin  floating tablets:
Table: 12 : Quantity of Raw Materials per Tablet (In mg)
Ingredients
F1
(mg)
F2
(mg)
F3
(mg)
F4
(mg)
F5
(mg)
F6
(mg)
F7
(mg)
F8
(mg)
F9
(mg)
Gabapentin 600 600 600 600 600 600 600 600 600
PEO 150 175 200 _ _ _ _ _ _
HPMC
K100M
_ _ _ 150 175 200 _ _ _
Sodium
CMC
_ _ _ _ _ _ 150 175 200
MCC 75 60 45 75 60 45 75 60 45
Lactose 30 20 10 30 20 10 30 20 10
PVP 50 50 50 50 50 50 50 50 50
Aerosil 10 10 10 10 10 10 10 10 10
Mg.stearate 10 10 10 10 10 10 10 10 10
NaHCo3 25 25 25 25 25 25 25 25 25
FORMULATION PROCEDURE87, 88:
Direct compression method:
These formulations are prepared by direct compression technique.
The following steps were taken while preparation of Gabapentin floating tablets
1. In each formulation Gabapentin, HPMC K100M, and all ingredients were
mixed and pass through 40#.
2. All the ingredients were mixed thoroughly by triturating up to 15
minutes.
3. The powder mixture was lubricated with magnesium stearte and also add
aerosol.
4. The tablets were prepared by using direct compression method.
EVALUATION OF GABPENTIN FLOATING TABLETS:
Lubricated blends of all formulations was examined and determined Angle
of repose, Loss on drying, Bulk density, tapped density, Carr’s index and Hausner’s
ratio as procedure given in preformulation section. All observations are given in
results and discussion section.
EVALUATION OF GABPENTIN FLOATING TABLETS:
a)TABLET DESCRIPTION89:
General appearance of tablet involves the measurement of a number
of attributes such as a tablet’s size, shape, color, presence or an odor, taste, surface
texture, physical flaws and consistency and legibility of any identify markings.
b) TABLET DIMENSIONS:
Thickness and were measured using a calibrated vernier caliper. Three
tablets of each formulation were taken randomly and thickness was measured
individually.
c) HARDNESS:
Hardness indicates the ability of a tablet to withstand mechanical shocks while
handling. The hardness of the tablets was determined using Monsanto hardness
tester. It is expressed in kg/cm2. Three tablets were randomly picked and hardness of
the tablets was determined88.
d) FRIABILITY TEST:
The friability of tablets was determined using Roche friabilator. It is
expressed in percentage (%). Twenty tablets were initially weighed (w0 initial) and
transferred into friabilator. The friabilator was operated at 25rpm for 4 minutes or
run up to 100 revolutions90. The tablets were weighed again (w).  The % friability
was then calculated by
Percentage of Friability = 100 (1-w/w0)
Percentage friability of tablets less than 1% is considered acceptable.
e) WEIGHT VARIATION TEST:
Twenty tablets were selected at random and the average weight was
determined91. Not more than two of the individual weights deviate from the average
weight by more than the percentage deviation shown in table and none deviates by
more than twice the percentage. USP official limits of percentage deviation of tablet
are presented in the Table 13.
Table.13: Weight Variation Tolerances for Uncoated Tablets
S. NO.
AVERAGE WEIGHT OF
TABLETS (mg)
MAXIMUM % DIFFERENCE
ALLOWED
1. 130 or Less 10
2. 130 to 324 7.5
3. More than 324 5.0
% Maximum positive deviation = (WH –A/ A) x 100
% Minimum negative deviation = (A-WL/ A) x 100
Where,
WH = Highest weight in mg.
WL = Lowest weight in mg.
A    = Average weight of tablet in mg.
f) TEST FOR CONTENT UNIFORMITY:
Chromatographic conditions:
Equipment : High performance liquid chromatography equipped with
Auto Sampler and DAD or UV detector.
Column : C18 (4.6 x 250mm, 5 m, Make: chromatopak) or equivalent
Flow rate : 1.2 ml per min
Wavelength : 210 nm
Injection volume : 20 l
Column oven : Ambient
Run time : 12 min
PREPARATION OF PH 6.9 BUFFER SOLUTION:
7gms of Potassium dihydrogen orthophosphate was weighed and taken in 1000
ml beaker. It is been dissolved and diluted with 1000 ml of HPLC water. And now
this solution has been adjusted to PH 6.9 with KOH.
PREPARATION OF MOBILE PHASE:
940 ml (94%) of above prepared buffer solution is been mixed up with 60 ml
(6%) of Acetonitrile HPLC and was degassed in ultrasonic water bath for 5 minutes.
And this solution is been filtered through 0.45µ filter under vaccum
filtration.
STOCK SOLUTION:
100mg of Gabapentin was taken into a 100 ml volumetric flask and to it small
amount of HPLC water (10 ml) is been added and is kept for sonication for the drug
to get properly dissolved and after that it is made up to 100 ml with mobile phase
which has been prepared  before thus 1000 ppm concentration of stock solution is
been prepared.
STANDARD SOLUTION:
2 ml of stock solution is taken and this is made up to 20 ml with the mobile
phase. 100 ppm concentration of solution is prepared. From this 4 ml was taken and
diluted to10 ml with mobile phase used as diluent’s solution. And peak areas of the
solution are taken at 210 nm in HPLC.
SAMPLE PREPARATION:
Ten tablets were individually weighed and crushed. A quantity of powder
equivalent to 100 mg of drug was taken and dissolved in 100 ml of mobile phase.
And from that 2ml is taken and is diluted with 20 ml of mobile phase. Further take
4ml solution and make upto 1 0ml with mobile phase and is been kept in HPLC at
210 nm in order to obtain a peak area.
Procedure: Separately inject standard preparations and sample preparations,
record the chromatograms, and measure the responses for analyte peaks. Calculate
the quantity as % drug release.
Calculation:
Assay % =
AT WS           DT          P           Avg. Wt
--------------- x ----------x --------- x ----------x------------------ X 100
AS DS          WT       100       Label Claim
Where:
AT = Peak Area of Gabapentin obtained with test preparation
AS = Peak Area of Gabapentin obtained with standard preparation
WS = Weight of working standard taken in mg
WT = Weight of sample taken in mg
DS = Dilution of Standard solution
DT  = Dilution of sample solution
P     = Percentage purity of working standard
8.5 BUOYANCY / FLOATING TEST92,93:
The time between introduction of dosage form and its buoyancy on the simulated
gastric fluid and the time during which the dosage form remain buoyant were
measured. The time taken for dosage form to emerge on surface of medium called
Floating Lag Time (FLT) or Buoyancy Lag Time (BLT) and total duration of time
by which dosage form remain buoyant is called Total Floating Time (TFT). The In
vitro buoyancy was determined by floating lag time. The tablets were placed in a
100 ml beaker containing 0.1N HCL. The time required for the table to rise to the
surface and float was determined as floating lag time. The duration of time the
dosage form constantly remained on the surface of the medium was determined as
the total floating time.
8.6 SWELLING STUDIES94:
The swelling behavior of dosage unit can be measured either by studying its
dimensional changes, weight gain or water uptake. The water uptake study of the
dosage form was conducted by using USP dissolution apparatus-II in a 900 ml of
distilled water which was maintained at 37o + 0.5oC, rotated at 50 rpm. At selected
regular intervals the tablet was withdrawn and weighed. Percentage swelling of the
tablet was expressed as percentage water uptake (%WU)
%WU = (Wt - Wo) * 100 / Wo
Where Wt is the weight of the swollen tablet and   Wo   is the initial weight of the
tablet.
IN- VITRO DRUG RELEASE STUDY:
Dissolution Parameters:
Medium                  : 0.1 N HCL.
Apparatus               : USP – Type II (Paddle).
RPM                      : 100.
Temperature           : 37o± 0.50 C.
Medium Volume    : 900 ml
Chromatographic conditions:
Equipment : High performance liquid chromatography equipped
with Auto Sampler and DAD or UV detector.
Column : C18 (4.6 x 250mm, 5 m, Make: chromatopak) or
equivalent
Flow rate : 1.2 ml per min
Wavelength : 210 nm
Injection volume : 20 l
Column oven : Ambient
Run time : 12 min
Limits:
According to USP-29 Specification
At 1st hour -- between 10-25%
At 9th hour -- between 45-85%
At 12 thhour -- no less than 70%
PREPARATION OF PH 6.9 BUFFER SOLUTION:
7gms of Potassium dihydrogen orthophosphate was weighed and taken in 1000
ml beaker. It is been dissolved and diluted with 1000 ml of HPLC water. And now
this solution has been adjusted to PH 6.9 with KOH.
PREPARATION OF MOBILE PHASE:
940 ml (94%) of above prepared buffer solution is been mixed up with 60 ml (6%)
of Acetonitrile HPLC and was degassed in ultrasonic water bath for 5 minutes. And
this solution is been filtered through 0.45µ filter under vaccum filtration.
PREPARATION OF STANDARD DRUG SOLUTION:
Stock solution:
100mg of Gabapentin was taken into a 100 ml volumetric flask and to it small
amount of HPLC water (10 ml) is been added and is kept for sonication for the drug
to get properly dissolved and after that it is made up to 100 ml with mobile phase
which has been prepared  before thus 1000 ppm concentration of stock solution is
been prepared.
STANDARD SOLUTION:
2 ml of stock solution is taken and this is made up to 20 ml with the mobile
phase. 100 ppm concentration of solution is prepared. From these different dilutions
where prepared like 20µg/ml, 30µg/ml, 40µg/ml, 50µg/ml, 60µg/ml respectively
with mobile phase used as diluent’s solution. And peak areas of this solutions are
been taken at 210 nm in HPLC.
SAMPLE PREPARATION:
Set the dissolution parameters as mentioned above. Place the formulated
tablets in dissolution vessels and operate the apparatus for specified time. At the end
of the specified time, with draw about 5 ml of the solution from a zone mid way
between the dissolution medium and the top of the rotating basket, not less than 1cm
from then vessel wall
Procedure:
In-vitro release studies were carried out using USP Type 1 apparatus
(rotating basket). 900 ml of 0.1 N HCl was taken in dissolution vessel and the
temperature of the medium was maintained at 370C0.50C. The speed was 100 rpm.
5ml of sample was withdrawn at pre-determined time intervals and same volume of
fresh medium was replaced. The samples are filtered with 0.45 filter medium. And
the samples are loaded in HPLC and record the chromatograms and measure the
responses for analytic peaks. Calculate the quantity as % drug release.
Calculations
% of drug release:
AT WS           900          P
--------------- x ----------x --------- x ----------x 100
AS DS          WT       100
AT = Peak Area of Gabapentin obtained with test preparation
AS = Peak Area of Gabapentin obtained with standard preparation
WS = Weight of working standard taken in mg
WT = Weight of sample taken in mg
DS = Dilution of Standard solution
P     = Percentage purity of working standard
KINETIC DATA ANALYSIS 95,96
The results of in vitro release profile obtained for all the formulations were plotted
in modes of data treatment as follows: -
1. Zero - order kinetic model - Cumulative % drug released versus time.
2. First – order kinetic model - Log cumulative percent drug remaining versus
time.
3. Higuchi’s model - Cumulative percent drug released versus square root of
time.
4. Korsmeyer equation / Peppa’s model - Log cumulative percent drug released
versus log time.
1. Zero order kinetics:
Zero order release would be predicted by the following equation: -
At = A0 – K0t
Where,
At = Drug release at time‘t’.
A0 = Initial drug concentration.
K0 = Zero - order rate constant (hr-1).
When the data is plotted as cumulative percent drug release versus time, if the plot is
linear then the data obeys Zero – order equal to K0.
2. First Order Kinetics:
First – order release would be predicted by the following equation:-
Log C = log C0 – Kt / 2.303
Where,
C = Amount of drug remained at time‘s’.
C0 = Initial amount of drug.
K   = First – order rate constant (hr-1).
When the data is plotted as log cumulative percent drug remaining versus time
yields a straight line, indicating that the release follow first order kinetics. The
constant ‘K’ can be obtained by multiplying 2.303 with the slope values.
3. Higuchi’s model:
Drug release from the matrix devices by diffusion has been described by
following           Higuchi’s classical diffusion equation:
Q = [Dε / τ (2 A - εCs) Cst] ½
Where,
Q = Amount of drug released at time’s’.
D = Diffusion coefficient of the drug in the matrix.
A = Total amount of drug in unit volume of matrix.
Cs = the solubility of the drug in the matrix.
ε = Porosity of the matrix.
τ = Tortuosity.
t = Time (hrs) at which ‘q’ amount of drug is released.
Above equation may be simplified if one assumes that ‘D’, ‘Cs’ and ‘A’ are
constant. Then equation becomes: -
Q = Kt1/2
When the data is plotted according to equation i.e. cumulative drug release versus
square root of time yields a straight line, indicating that the drug was released by
diffusion mechanism. The slope is equal to ‘K’ (Higuchi’s 1963).
4.  Korsmeyer equation / Peppa’s model:
To study the mechanism of drug release from the floating tablets of
Gabapentin, the release data were also fitted to the well-known exponential equation
(Korsmeyer equation/ peppa’s law equation), which is often used to describe the
drug release behavior from polymeric systems
DIFFUSION COEFFICIENT:
From the Korsemeyer peppas equation, diffusion coefficient is determined using
the equation
Mt/M∞=ktn
Where, Mt/M∞ represents the fraction of drug release at time t, k is the release
rate constant and n is the diffusion coefficient.
A plot of log cumulative % drug release vs. log time was made. Slope of the
line was n. The n value is used to characterize different release mechanisms as given
in Table14, for the cylindrical shaped matrices. Case-II generally refers to the
erosion of the polymeric chain and anomalous transport (Non-Fickian) refers to a
combination of both diffusion and erosion controlled-drug release.
Diffusion Exponent and Solute Release Mechanism for Cylindrical Shape
Table : 14 Limits
STABILITY STUDIES97:
The purpose of stability testing is to provide evidence on how the quality of a
drug substance or drug product varies with time under the influence of a variety of
environmental factors such as temperature, humidity and light.  And to establish a
retest for the drug substance or a shelf life for the drug product and recommended
storage conditions.
The storage conditions used for stability studies were Accelerated condition
(40°C±2°C/75%RH). Stability study was carried out for the optimized formulation.
Tablets of optimized formulation were striped packed and kept in humidity chamber
for 90 days on above mention temperature.
Diffusion exponent (n) Overall solute diffusion mechanism
0.45 Fickian diffusion
0.45 < n < 0.89 Anomalous (non-Fickian) diffusion
0.89 Case-II transport
n > 0.89 Super case-II transport
The following tests are performed after 90 days.
Tests performed:
 Drug content
 Dissolution profile
 Test for other physical parameters (hardness, weight variation,
friability).
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RESULTS AND DISCUSSION
PREFORMULATION STUDY
a)Identification of drug and drug-polymer compatibility study
FTIR studies
The FTIR spectra of the pure drug, excipient and physical mixture of drug and
excipient were recorded in between 400-4000 wave number (cm-1).  No peaks are
observed which interfere with the main drug peaks.  The following spectrum and
table shows IR spectrum for drug and polymer and the wave number of
characteristic bands for the same.
The IR Spectrum preview pictures are as follows:
Figure  18 : FTIR Spectra of gabapentin
Table 16 : FTIR peak areas of gabapentin
S.No Observed
Frequency
Reported
Frequency (cm-
1)
Functional
group(cm-1)
1 3417.20 3500-3300 N-H
2 2930.56,2859.59 2960-2850 C-H
3 2613.23,2426.32 2800-2340 OH
4 2142.72 2100-2200 C≡C
Figure 19 : FTIR Spectra of Sodium Carboxy methyl Cellulose
Table 17 : FTIR peak areas of Sodium Carboxy methyl cellulose
S.No Observed
Frequency
Reported
Frequency (cm-
1)
Reported
Frequency (cm-
1)
1 3416.19 3500-3300 N-H
2 2933.84 2960-2850 C-H
3 2426.45 2800-2340 OH
4 1617.92 1680-1630 C=O
5 1115.88 1200-1025 C-N
Figure 20 :FTIR Spectra of Polyethylene Oxide
Table 18  : FTIR peak areas of Polyethylene Oxide
S.No Observed
Frequency
Reported
Frequency (cm-
1)
Reported
Frequency (cm-
1)
1 3416.55 3500-3300 N-H
2 2932.97 2960-2850 C-H
3 2426.49 2800-2340 OH
4 1617.81 1680-1630 C=O
5 1115.96 1200-1025 C-N
Figure 21:FTIR Spectra of HPMC K100M
Table 19  :FTIR peak areas of HPMC K100M
S.No Observed
Frequency
Reported
Frequency (cm-
1)
Reported
Frequency (cm-
1)
1 3454.14 3500-3300 N-H
2 2926.37 2960-2850 C-H
3
2426.31
2800-2340 OH
4
1635.42
1680-1630 C=O
5
1384.05
1310-1410 C-O
6
1118.63
1200-1025 C-N
Figure 22 : FTIR Spectra of Gabapentin, polymers and excipients
Table 20 : FTIR peak areas of gabapentin+polymers+excipients
S.No Observed
Frequency
Reported
Frequency (cm-
1)
Reported
Frequency (cm-
1)
1 34515.64 3500-3300 N-H
2 2930.70 2960-2850 C-H
3
2428.51
2800-2340 OH
4
1637.65
1680-1630 C=O
5
1384.11
1310-1410 C-O
6 1193.29 1200-1025 C-N
a) Melting point of drug
The melting point of gabapentin was determined by capillary method,
melting point of gabapentin was found to be 162-166oC . Melting point compared
with USP standards that showed that drug is pure.
b) Solubility analysis
Gabapentin samples are examined and it was found to be soluble in water
and slightly soluble methanol, dimethyl formamide. It also dissolves in dilute alkali
and in dilute acids.
a) POWDER CHARACTERIZATION:
Table 21 : Observation of organoleptic properties of gabapentin
TEST SPECIFICATION OBSERVATION
Colour White or almost white powder White powder
Odour --- Odourless
i) Angle of repose
It was determined as per procedure given in material and methodology
section.
Table 22 :  Determinations of Angle of repose of Gabapentin
Material Angle of repose
Gabapentin Raw material 27°25"
The results indicating that the raw material has good flow property.
ii) Loss of Drying
It was determined as per procedure given in methodology. The results are as
follows
Table 23 : Observations for loss on drying of Gabapentin
Test Loss on drying Observation
Loss on drying Not more than 0.5% 0.31%
The loss drying of drug was founded as 0.31 which is with in the limit.
iii) Flow properties
The method to determine the flow properties are given in methodology
.
Table 24 :  Flow properties of pure drug Gabapentin
Material Bulk density Tapped
density
Carr’s index
(%)
Hausner ratio
(%)
Gabapentin raw
material
0.21 0.34 10.52 1.104
The results are clearly indicating that the gabapentin raw material has  free flow .
iv)Physical compatibility test
The method for determination of physical compatibility test was given in
methodology.
Table 25 : Observation for physical compatibility test
Test Observation Inference
Description No colour change was observed Complies with the condition
The physical compatibility evaluation was performed in visual basis. The
study implies that the drug, polymer and other excipients were physically
compatible with each other as there was no change of physical description.
Table 26:  Standard curve of Gabapentin
The linear regression analysis was done on absorbance data points. A straight line
generated to facilitate the calculation of amount of drug, the equation is as follows:
Y = mx + c
Where Y=absorbance, m=slope, x=concentration
S.NO Concentration (µg/ml) Average peak area
01 20 1789722
02 30 2660326
03 40 3579445
04 50 4475206
05 60 5343689
Figure 23 : Standard curve of Gabapentin
EVALUATION OF POWDER CHARACTERISTICS :
Table 27 : Evaluation of powder characteristics of F1-F9 Formulations
Formulation
code
Angle of
repose
(degree±
SD)
Bulk
Density
(gm/ml±SD)
Tapped
Density
(gm/ml±SD)
Carr’s
index
(%± SD)
Hausner
ratio
(%± SD)
F1 26.42±0.04 0.311±0.02 0.337±0.02 14.35±0.06 1.03±0.05
F2 27.17±0.01 0.325±0.04 0.359±0.04 15.61±0.07 1.23±0.04
F3 29.01±0.03 0.339±0.06 0.361±0.07 14.64±0.04 1.14±0.02
F4 27.57±0.07 0.307±0.04 0.317±0.06 13.46±0.01 1.13±0.06
F5 26.77±0.09 0.287±0.03 0.321±0.05 12.29±0.05 1.25±0.03
F6 25.61±0.06 0.271±0.01 0.345±0.01 16.35±0.03 1.15±0.01
F7 26.16±0.03 0.297±0.04 0.357±0.03 14.46±0.07 1.20±0.03
F8 29.11±0.09 0.307±0.05 0.366±0.02 15.61±0.04 1.19±0.05
F9 28.05±0.02 0.320±0.06 0.359±0.04 13.85±0.09 1.21±0.00
The powders were evaluated for various flow properties. The powders of all
batches showed good flow properties evident from the results shown in table-27.
The angle of repose values were ranged from 25.61±0.06to 29.11±0.09. The results
were found to be below 30; hence they have good flow ability. The Carr’s index
value ranged from 12.29±0.05to 16.35±0.03 and Hausner’s ratio value ranged from
1.03±0.05to 1.25±0.03 hence they have good flow and free flow ability.
Table 28 : Physical Evaluation of formulated tablets
Formulation
code
Weight
variation
(n=20)
(mg ± SD)
Hardness
(kg/cm2±SD)
Friability
(%)
Drug
content
(%± SD)
Thickness
(%± SD)
F1 952±0.29 6.6±0.1 0.69 99.13±0.04 5.2±0.007
F2 951±0.67 6.4±0.2 0.67 98.19±0.01 5.3±0.006
F3 949±0.45 7.0±0.3 0.74 99.29±0.12 5.2±0.011
F4 951±0.71 6.7±0.5 0.71 98.19±0.09 5.3±0.008
F5 948±0.15 7.2±0.2 0.65 99.17±0.07 5.2±0.009
F6 952±0.31 6.8±0.4 0.63 98.61±0.03 5.2±0.013
F7 949±0.04 6.5±0.3 0.76 99.13±0.17 5.3±0.004
F8 948±0.71 7.3±0.3 0.70 99.11±0.14 5.2±0.012
F9 951±0.52 7.4±0.5 0.68 98.21±0.05 5.3±0.05
The formulated sustained release matrix tablets were then evaluated for various
physical characteristics like thickness, weight variation, hardness, friability, drug
content. The weight variation of tablets was uniform in all formulations and ranged
from 948±0.71to 952±0.29. The hardness of the prepared tablets was ranged from
6.4±0.2 to 7.4±0.3, friability values were ranged from 0.63 to 0.76. Drug content of
tablets was ranged from 98.11±0.03 to 99.91±0.14, thickness of tablets was uniform
and values are ranged from 5.2±0.013to 5.3±0.006.
Table : 29 Floating time of gabapentin tablets
Formulation
Code
Lag time
(seconds)
Total floating
Time (hours)
F1 69 >12
F2 56 >12
F3 60 >12
F4 70 >12
F5 59 >12
F6 50 >12
F7 65 >12
F8 74 >12
F9 68 >12
Table 30:  Percentage  swelling index of formulated tablets
Formulation
Code
Percentage Swelling index
Time (hours)
1 2 3 4 5
F1 30.06 41.68 59.78 71.56 82.64
F2 32.45 46.65 62.54 78.58 89.09
F3 29.26 49.64 63.24 86.35 92.64
F4 25.98 42.82 64.68 79.04 88.97
F5 27.57 54.65 68.12 80.5 92.36
F6 29.34 57.68 73.56 84.75 97.51
F7 28.00 41.76 50.99 71.24 86.29
F8 30.11 44.38 58.49 77.63 90.23
F9 26.16 49.25 64.21 81.87 94.19
The swelling behaviors all formulated tablets were calculated and results were
ranging from 25.98 to 97.51. The results are clearly indicating that swelling capacity
increases by increasing polymer concentration.
Figure 24: Percentage swelling index plot of F1-F3
Figure 25: Percentage swelling index plot of F4-F6
Figure 26: Percentage swelling index plot of F7-F9
Table 31: Invitro drug release study of formulated sustained release
formulations
TIME
(hours)
CUMULATIVE PERCENT DRUG RELEASE (%)
F1 F2 F3 F4 F5 F6 F7 F8 F9
0 0 0 0 0 0 0 0 0 0
1 33.25 27.46 21.31 35.33 24.96 21.32 30.66 25.57 24.82
2 50.68 44.74 32.64 51.24 46.76 32.17 48.45 49.68 38.95
4 75.62 62.10 58.21 79.11 59.47 59.09 72.04 65.49 52.14
6 82.51 84.45 64.54 92.21 86.88 66.70 89.34 78.64 76.31
8 98.25 93.48 78.90 98.98 92.36 85.68 99.69 91.45 88.49
10 - 98.38 84.41 - 99.23 94.58 - 99.10 92.62
12 - - 99.08 - - 99.96 - - 98.48
Figure 27: Invitro drug release of F1-F5
Figure 28: Invitro drug release of F6-F9
Figure 29: Standard peak of gabapentin optimum formulation
Figure 30: Peak obtained after 1hour dissolution
Figure 31: Peak obtained after 2 hours dissolution
Figure 32: Peak obtained after 4 hours dissolution
Figure 33: Peak obtained after 6 hours dissolution
Figure 34: Peak obtained after 8 hours dissoluton
Figure 35: Peak obtained after 10 hours dissolution
Figure 36: Peak obtained after 12 hours dissolution
The formulated  floating sustained released matrix tablets were then subjected to
invitro dissolution test for evaluating drug release from the formulation. The Invitro
dissolution test was carried out in 900 ml of 0.1N Hcl in USP-II paddle type
apparatus at 100 rpm and 37±0.5oC. The results of dissolution study was depends on
polymer concentration. Formulation containing HPMC K100M had given drug
release 99.85% in 12 hrs. Then the formulations containing HPMC K100M were
given better release profiles when compared with formulations containing Sodium
CMC, PEO.
KINETIC STUDIES OF GABAPENTIN FLOATING TABLETS:
Table 32: Chart for kinetic study
Time
(hours)
Log
Time
√Time cumulative
% drug
release
Log
cumulative
% drug
release
cumulative
% drug
remained
Log
cumulative
% drug
remained
0 0 0 0 0 100 2.000
1 0 1.000 21.32 1.328 78.68 1.895
2 0.301 1.414 32.17 1.507 67.83 1.831
4 0.602 2.000 59.09 1.771 40.91 1.611
6 0.778 2.449 66.70 1.824 33.30 1.522
8 0.903 2.828 85.68 1.932 14.32 1.155
10 1.000 3.162 94.58 1.975 5.42 0.733
12 1.079 3.464 99.96 1.999 0.150 -0.823
Figure 29: Zero order plot for F6
Figure30: First order plot for F6
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Figure 31: Higuchi plot for F6
Figure 32: Korsemeyer Peppas plot for F6
KINETICS OF DRUG RELEASE
Table 33: Kinetic studies of F6
Formulation Regression
coefficient of
Zero order
Regression
coefficient of
First order
Order of release
F6 0.952 0.898 Zero order release
Table34 :Kinetic studies of F6
Formulation Higuchi  Model Korsemeyer Peppas
Model
Slope R2 Slope (n) R2
F6 30.74 0.986 0.668 0.993
In order to determine the mechanism of drug release form the formulations,
the invitro dissolution data was fitted to Zero order, First order, Higuchi plot and
Korsemeyer-peppa’s plot was drawn and interpretation of release exponent value (n)
was calculated . The results of R2 for zero and first order were obtained as 0.952 and
0.798. Based on that we will confirm the optimized formulation followed Zero order
release.
The drug release was diffusion controlled as the plot of optimized formulation F6
was found 0.986 as regression co-efficient in higuchi plot. From Korsemeyer
peppa’s plot the release exponent value n was found as 0.668 and it was confirmed
as the release of drug from the formulation was founded as anomalous non-fickian
transport of diffusion.
STABILITY STUDIES:
The optimized sustained release formulation was subjected to stability studies at
40oC ± 2oC / 75% RH ± 5% for 3 months.
The product was evaluated for following parameters:
 Weight variation
 Hardness
 Friability
 Drug content
 Dissolution analysis
Storage condition at 40°C±2°C/75%RH±5%:
Table35: Stability data
TEST 30 days 60 days 90 days
Weight
variation
949±0.55 949±0.84 948±0.69
Hardness 6.8 6.8 6.7
Friability 0.64 0.64 0.63
Drug content 99.68±0.05 99.24±0.06 99.24±0.01
Table 36: Dissolution data of percent cumulative drug release for formulation
F6
Time (hrs) 0 days 30 days 60 days 90 days
0 0 0 0 0
1 21.32 21.29 21.21 21.18
2 32.17 32.15 32.10 32.02
4 59.09 59.00 58.92 58.85
6 66.70 66.64 66.58 66.50
8 85.68 85.62 85.59 85.53
10 94.58 94.55 94.50 94.48
12 99.85 99.80 99.72 99.67
Figure 33: Dissolution stability data for sample F6
The stability studies for optimized formulation F6 was carried out based accelerated
stability conditions and study of various parameters carried out at 0, 30, 60, 90 days
of intervals and the results found satisfactorily and that reveals that the optimized
formulation was stable under accelerated condition.
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SUMMARY AND CONCLUSION
The main objective of the present study was to develop floating sustained
release formulation containing 600 mg of gabapenin for once daily therapy by using
polymers like HPMC K100M, Sodium CMC, PEO. Gastroretentive Drug Delivery
System improves the bioavailability and therapeutic efficiency of drug.
In the preformulation FTIR study was carried out for pure drug (Gabapentin),
gabapentin   and excipients. It has not shown any interaction .
The formulations were prepared by direct compression method . The angle of
repose values of all the formulations ranged from 25.61±0.03 to 28.05±0.02. Bulk
and tapped densities are used for the measurement of compressibility index.The bulk
and tapped density values of all the formulations were ranged  from 0.271±0.01 to
0.339±0.06 and 0.317±0.06 to 0.366±0.02  respectively. The carr’s index and
hausner’s ratio values for all formulations were ranged from 12.29±0.05 to
16.35±0.03 and 1.03 ±0.05 to 1.25±0.03 respectively. Thus all formulations
exhibited good flow characteristics.
The prepared floating sustained release tablets were evaluated for various
parameters like thickness, weight variation,  hardness, friability  and drug content
uniformity. The  thickness of tablets in all formulations were ranged from
5.2±0.06mm to 5.3±0.05mm.  The weight variation of tablets in all formulations
were ranged  from 948±0.15% to 952.61±0.31%.The hardness of all the
formulations F1-F9 was found to be 6.4±0.2(kg/cm2) to 7.4±0.5(kg/cm2). The
friability of all the F1-F9 formulations was found to be 0.63% to 0.76% respectively.
Drug content of all the formulations were ranged from 99.11±0.14% to
99.61±0.03%. The buoyancy lag time of all the formulations were ranged from  50
Sec to 70 Sec.
Compared to all formulations F6 showed the best buoyancy lag time, the buoyancy
lag time for F6 was foud to be 50Sec.Total floating time of all formulations was
found to be >12 hours. The formulation  containing  HPMC K 100M shows the
higher swelling compared to that of the formulations containing PEO, Sodium
CMC.
The prepared tablets were then subjected to dissolution test for evaluating the
invitro drug release.The dissolution studies were carried out in 0.1N Hcl in USP II
appatarus at 37±0.5oC. The results of the dissolution studies indicated that the
polymer concentration is having a substantial effect on the drug release from the
tablets. Formulation F6 gave better sustained drug release and floating properties in
comparision to the other formulations. This formulation took 50Sec to become
buoyant.
The kinetic study was carried out for F6 formulation which showed that the drug
release follows zero order kinetics.
The stability studies were carried out for F6 formulation at 40oC ± 2oC / 75% RH
± 5% for 3months. Data revelead that there was no considerable difference.
From the above study, it can be concluded that F6 is the optimized formulation
which has shown better buoyancy time 50 Sec and drug release 99.85% . However,
further in vivo studies can be carried out to support the results.
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